January | February | March | April | May | June | July | August | September | October | November | December |
| ||||||
| Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
| AEI to award Aptatargets funding to support a phase IIa study of Aptoll for acute myocardial infarction | Aptatargets SL | Spanish State Research Agency | $2.55 | 1/3/2023 |
| NIA to award EIP Pharma funding to conduct the phase IIb study of neflamapimod in dementia with Lewy bodies patients | EIP Pharma Inc. | National Institute on Aging | $21.00 | 1/18/2023 |
| DoD to award ENA Respiratory funding to support the research and development of INNA-051 against respiratory viral infections | Ena Respiratory Pty Ltd. | U.S. Department of Defense | $4.38 | 1/9/2023 |
| NSW government to award Garvan Institute funding to develop mRNA vaccine against COVID-19 | Garvan Institute of Medical Research | NSW Government | Payment unspecified | 1/25/2023 |
| CF Foundation to award Gensaic funding to develop gene therapy for cystic fibrosis | Gensaic | Cystic Fibrosis Foundation | $3.50 | 1/9/2023 |
| Crohn’s and Colitis Foundation to award Giiant Pharma funding to support the development of GT-2108 against ulcerative colitis | Giiant Pharma Inc. | Crohn’s and Colitis Foundation | $0.50 | 1/10/2023 |
| McGill University Health Centre Foundation to award Hemostemix funding to complete a phase II, double-blind, randomized, clinical trial of ACP-01 for treating ischemic cardiomyopathy | Hemostemix Inc. | McGill University Health Centre Foundation | $0.25 | 1/19/2023 |
| DoD to award HSS funding to conduct research on lupus flares | Hospital for Special Surgery NY | U.S. Department of Defense | Payment unspecified | 1/5/2023 |
| California Institute for Regenerative Medicine to award Immusoft funding to support the phase I study of ISP-001 for the treatment of mucopolysaccharidosis type I | Immusoft Corp. | California Institute for Regenerative Medicine | $8.00 | 1/27/2023 |
| Bill & Melinda Gates Foundation to award Lumen Bioscience funding to support a phase II study of LMN-101 in healthy volunteers challenged with Campylobacter jejuni | Lumen Bioscience Inc. | Bill & Melinda Gates Foundation | $5.00 | 1/5/2023 |
| Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator to award Lumen Bioscience funding for lead optimization of an anti-campylobacter/anti-ETEC VHH cocktail to prevent serious diarrheal diseases | Lumen Bioscience Inc. | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $2.80 | 1/5/2023 |
| U.S. Army Medical Research and Development Command to award Lumen Bioscience funding to support the clinical testing of a tablet form of anti-campylobacter/anti-ETEC VHH cocktail product | Lumen Bioscience Inc. | U.S. Army Medical Research and Development Command | $4.00 | 1/5/2023 |
| ADDF to award MGH funding to discover and develop therapies against Alzheimer's disease | Massachusetts General Hospital | Alzheimer's Drug Discovery Foundation | $0.60 | 1/12/2023 |
| GIRF to award Mayo Clinic funding to support colorectal cancer research projects | Mayo Clinic | Gastro-Intestinal Research Foundation Inc. | $6.00 | 1/24/2023 |
| French Government to award NFL Biosciences funding to support PRECESTO phase IIa clinical trial to evaluate NFL-101 against smoking cessation and NRTs | NFL Biosciences SA | French Government | $0.21 | 1/11/2023 |
| JDRF to award Panbela funding to conduct phase II study of CPP-1X-T for recent onset type 1 diabetes | Panbela Therapeutics Inc. | Juvenile Diabetes Research Foundation | Payment unspecified | 1/11/2023 |
| CF Foundation to invest in Recode Therapeutics for the development of mRNA-based therapeutic against cystic fibrosis | Recode Therapeutics Inc. | Cystic Fibrosis Foundation | $15.00 | 1/10/2023 |
| NIDDK to award a SBIR Phase II grant to further conduct proof-of-concept testing of Rise Therapeutics' R-2487 for type 1 diabetes | Rise Therapeutics LLC | National Institute of Diabetes and Digestive and Kidney Diseases | Payment unspecified | 1/10/2023 |
| NIGMS to award Rosalind Franklin University of Medicine funding to study therapeutic strategies against multidrug resistance | Rosalind Franklin University of Medicine & Science | National Institute of General Medical Sciences | $1.30 | 1/11/2023 |
| Sab Biotherapeutics received an additional $8.2M from the U.S. Department of Defense related to the discontinued COVID-19 prototype research and development contract | Sab Biotherapeutics Inc. | U.S. Department of Defense | $8.20 | 1/18/2023 |
| Sol Goldman Charitable Trust to award Salk Institute funding to conduct research on multiple sclerosis treatments | The Salk Institute for Biological Studies | Sol Goldman Charitable Trust | $1.50 | 1/19/2023 |
| CEPI to award Tiba Biotech funding to evaluate RNABL RNA vaccine platform for Japanese encephalitis virus | Tiba Biotech | Coalition for Epidemic Preparedness Innovations | $2.00 | 1/12/2023 |
| LifeArc to award University College London funding to develop therapies for motor neuron disease | University College London | LifeArc | $1.17 | 1/24/2023 |
| GIRF to award University of Texas funding to support research projects on molecularly targeted therapies for BRAFmut colorectal tumor | University of Texas System | Gastro-Intestinal Research Foundation Inc. | $3.50 | 1/24/2023 |
| CEPI to award Vaxxas funding to develop HD-MAP technology for infectious diseases and COVID-19 | Vaxxas Pty Ltd. | Coalition for Epidemic Preparedness Innovations | $4.30 | 1/17/2023 |
| MJFF to award AC Immune funding to develop TDP-43 PET tracer program | AC Immune SA | Michael J. Fox Foundation for Parkinson's Research | $0.25 | 2/8/23 |
| Target ALS Foundation to award AC Immune funding to develop biofluid assays for detecting TDP-43-related neuropathology | AC Immune SA | Target ALS Foundation | $0.25 | 2/8/23 |
| MCDC to award Access to Advanced Health Institute funding to develop intranasal bivalent influenza RNA vaccine against infectious disease | Access to Advanced Health Institute | Medical CBRN Defense Consortium | $9.90 | 2/6/23 |
| Defense Innovation Uni of US DOD to award Access to Advanced Health Institute funding to develop an intranasal Pan-Viral countermeasure against respiratory viruses | Access to Advanced Health Institute | Defense Innovation Unit of the US Department of Defense | $3.00 | 2/15/23 |
| Eurostars to award Adjutec Pharma funding to develop APC-247 against bacterial infection | Adjutec Pharma AS | Eurostars | $3.32 | 2/15/23 |
| NIH to award Adolore funding to support the development of ADB-102 for chronic pain, including knee osteoarthritis and neuropathic pain | Adolore Biotherapeutics Inc. | National Institutes of Health | Payment unspecified | 2/22/23 |
| NHLBI to award Alveolus SBIR funding to support the development of RB-1000 for chronic obstructive pulmonary disease | Alveolus Bio Inc, | National Heart Lung and Blood Institute | $2.50 | 2/15/23 |
| National Cancer Institute to award Aprea Therapeutics funding to develop combination of DNA damage response inhibitors against high-grade serous ovarian cancer | Aprea Therapeutics Inc. | National Cancer Institute | $2.00 | 2/15/23 |
| CIHR to award BLR Bio funding to evaluate the effects of BLR-200 for scleroderma | BLR Bio LLC | Canadian Institutes of Health Research | $0.78 | 2/14/23 |
| Preeclampsia Foundation to award Boston University funding for the discovery of therapies against preeclampsia | Boston University | Recalcine Pharmaceutical Corp. | $0.10 | 2/8/23 |
| Cystic Fibrosis Foundation to award Cedars-Sinai funding to conduct research on cystic fibrosis | Cedars-Sinai Medical Center | Cystic Fibrosis Foundation | $0.50 | 2/24/23 |
| CIRM to award Cedars-Sinai funding to develop injectable pluripotent stem cell therapy against degenerated intervertebral discs | Cedars-Sinai Medical Center | California Institute for Regenerative Medicine | $2.00 | 2/28/23 |
| US DoD to award Children’s Hospital Los Angeles funding to develop therapies into diffuse intrinsic pontine glioma | Children's Hospital Los Angeles | U.S. Department of Defense | $1.00 | 2/22/23 |
| TeamConnor to award Children's Hospital of Philadelphia funding to support the research of single-cell multi-omics of pediatric lymphoma to identify novel targets | Childrens Hospital of Philadelphia | TeamConnor Childhood Cancer Foundation | Payment unspecified | 2/9/23 |
| TeamConnor Childhood Cancer Foundation to award Cincinnati Children's Hospital funding for research of diffuse midline gliomas with GD2-STAR-T cell immunotherapy | Cincinnati Children's Hospital Medical Center | TeamConnor Childhood Cancer Foundation | Payment unspecified | 2/9/23 |
| TeamConnor to award Cook Children's Hospital funding to support the research of precision medicine for relapsed neuroblastoma | Cook Children's Medical Center | TeamConnor Childhood Cancer Foundation | Payment unspecified | 2/9/23 |
| NSF to award Cytorecovery a Phase II SBIR grant to develop features to be embodied in the CytoR2 Platform for advanced cell sorting | Cytorecovery Inc. | National Science Foundation | $0.95 | 2/9/23 |
| TeamConnor Childhood Cancer Foundation to award Dana Farber Cancer Institute funding to develop treatments for Juvenile Myelomonocytic Leukemia | Dana-Farber Cancer Institute Inc | TeamConnor Childhood Cancer Foundation | Payment unspecified | 2/9/23 |
| NIH to award Dignify Therapeutics funding to support clinical development of DTI-117 for bladder and bowel dysfunction | Dignify Therapeutics Inc. | National Institutes of Health | $4.00 | 2/28/23 |
| DoD to award Eumentis funding to develop EM-113 for traumatic brain injury, including autism spectrum disorder | Eumentis Therapeutics Inc. | U.S. Department of Defense | $3.00 | 2/8/23 |
| CIRM to award Genascence funding to support a phase Ib study of GNSC-001 in knee osteoarthritis | Genascence Corp. | California Institute for Regenerative Medicine | $11.60 | 2/23/23 |
| Swedish Research Council to award Intelgenx funding to support clinical study of Montelukast Versafilm against Parkinson’s disease | Intelgenx Corp. | Swedish Research Council | $2.00 | 2/9/23 |
| Swedish Research Council to award Karolinska Institutet funding to conduct a study on the antibody for non-alcoholic fatty liver disease | Karolinska Institutet | Swedish Research Council | Payment unspecified | 2/3/23 |
| Machine Bio received grant from the Center for the Advancement of Science in Space Inc. and The Boeing to test its technology to synthesize protein from a DNA template in a single step onboard the international space station | Machine Bio Inc. | Center for the Advancement of Science in Space Inc. and The Boeing Co. | $0.50 | 2/21/23 |
| Cancer Council Victoria to award BDI grant to investigate on treatment strategies for prostate and bowel cancers | Monash Biomedicine Discovery Institute | The Cancer Council Victoria | $0.90 | 2/28/23 |
| Dutch Research Council to award Netherlands Cancer Institute a funding to support the research on DNA folding and impact on the development of cancer | Netherlands Cancer Institute | Dutch Research Council | $1.53 | 2/23/23 |
| Bpifrance to award NFL Bioscience funding to develop NFL-101 for the treatment of addictions and smoking cessation | NFL Biosciences SA | Epic Bpifrance | $1.74 | 2/20/23 |
| NIIMBL to award Northeastern University funding to improve mRNA vaccine potency assessment and prediction draft | Northeastern University | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 2/28/23 |
| The Michael J. Fox Foundation to award NRG Therapeutics funding to develop NRG’s program to develop inhibitors of the mitochondrial permeability transition pore as a treatment for Parkinson’s disease | NRG Therapeutics Ltd. | The Michael J. Fox Foundation | $0.50 | 2/23/23 |
| NIIMBL to award PATH Center for Vaccines funding to optimize mRNA vaccine potency assay platform for worldwide use | PATH Center for Vaccine Innovation and Access CVIA | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 2/28/23 |
| NCI to award POP funding to develop I-CPT with doxorubicin for hepatocellular carcinoma | POP Biotechnologies Inc. | National Cancer Institute | $2.00 | 2/1/23 |
| CIRM to award Rubedo funding to support the research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis | Rubedo Life Sciences Inc. | California Institute for Regenerative Medicine | $1.45 | 2/6/23 |
| California Institute for Regenerative Medicine to award Ryne Biotechnology funding to develop RNDP-001 for Parkinson’s disease | Ryne Biotechnology Inc. | California Institute for Regenerative Medicine | $4.00 | 2/15/23 |
| Cancer Prevention and Research Institute of Texas to award Salarius Pharmaceuticals funding to develop seclidemstat to treat Ewing sarcoma | Salarius Pharmaceuticals Inc. | Cancer Prevention and Research Institute of Texas | $1.48 | 2/16/23 |
| National Institute of Dental and Craniofacial Research to award Sinopia Biosciences to develop therapeutic candidates for oral mucositis | Sinopia Biosciences Inc. | National Institute of Dental and Craniofacial Research | Payment unspecified | 2/27/23 |
| NIH to award TargaGenix funding to develop TGX-1214 for PDAC | Targagenix Inc. | National Institutes of Health | $3.00 | 2/7/23 |
| MFCR to award NYU Grossman School of Medicine funding to develop small molecule inhibitors for pancreatic cancer | The Mark Foundation for Cancer Research | NYU Grossman School of Medicine | $1.00 | 2/8/23 |
| Endomimetics to award UAB funding to develop bioactive DPC material using Bionanomatrix to treat dental caries and other dental ailments | University of Alabama at Birmingham | Endomimetics LLC | $0.35 | 2/14/23 |
| DARPA to award UMSOM funding to develop bio-synthetic whole-blood product for trauma patients | University of Maryland School of Medicine | Defense Advanced Research Projects Agency | $46.40 | 2/4/23 |
| DeGregorio Family Foundation to award University of Miami Miller to target cancer stem cell by using experimental drugs | University of Miami Miller School of Medicine | DeGregorio Family Foundation | $0.07 | 2/17/23 |
| Department of Defense to award University of Miami funding to study the use of probenecid for male infertility after spinal cord injury | University of Miami Miller School of Medicine | U.S. Department of Defense | $3.25 | 2/24/23 |
| Leducq Foundation to award funding to the University of Queensland to develop mRNA vaccine for Strep A | University of Queensland | Leducq Foundation | $8.00 | 2/17/23 |
| NIAID to award Washington University funding to develop vaccine against norovirus and rotavirus infection | Washington University in St Louis | National Institute of Allergy and Infectious Diseases | $0.39 | 2/14/23 |
| NCI to award Weill Cornell Medicine funding to develop therapies against EBV causing lymphoma in HIV patients | Weill Cornell Medicine | National Cancer Institute | $4.20 | 2/23/23 |
| MFCR to award Yale University funding to develop CDK11B inhibitors for cancer | Yale University | The Mark Foundation for Cancer Research | $1.00 | 2/8/23 |
| National Research Council of Canada to award Arch Biopartners funding to develop Metablok for acute inflammation injury in the lungs, kidneys and liver | Arch Biopartners Inc. | National Research Council of Canada | $2.90 | 3/23/2023 |
| CMTRF to award Augustine Therapeutics funding to develop HDAC6 inhibitors, including AGT-216 against Charcot-Marie-Tooth disease | Augustine Therapeutics NV | CMT Research Foundation | Payment unspecified | 3/2/2023 |
| Parkinson's Foundation to fund research at Barrow Institute to study on targeting ACMSD for reducing brain inflammation, loss of brain cells in Parkinson's disease | Barrow Neurological Insitute | Parkinson’s Foundation | $0.80 | 3/7/2023 |
| Bill & Melinda Gates Foundation to award Delsitech funding to develop long-acting injectable formulations of HIV vaccines using Silica Matrix technology | Delsitech Ltd. | Bill & Melinda Gates Foundation | Payment unspecified | 3/16/2023 |
| NCI to award Emmyon Phase II SBIR grant to develop cancer induced skeletal muscle wasting therapeutics | Emmyon Inc. | National Cancer Institute | Payment unspecified | 3/7/2023 |
| Innovation Fund Denmark to award grant to Fluoguide for research and development of photothermal therapy using FG-001 against cancer | Fluoguide A/S | The Danish National Advanced Technology Foundation | $0.69 | 3/21/2023 |
| Eurostars to award Gain Therapeutics funding to develop small molecule allosteric regulators for the treatment of AAT deficiency | Gain Therapeutics Inc. | Eurostars | $1.23 | 3/21/2023 |
| Brain Tumour Research to award Institute of Cancer Research funding for the development of new therapies against brain cancer | Institute of Cancer Research UK | Brain Tumor Research Charity Grant | $2.93 | 3/14/2023 |
| BARDA to award IAVI funding to develop two recombinant vesicular stomatitis virus-vectored filovirus vaccine candidates | International AIDS Vaccine Initiative | Biomedical Advanced Research and Development Authority | $126.00 | 3/6/2023 |
| GRF to award Karolinska Institutet funding to conduct research on drug-driven identification of inflammatory pathways in retinal microglia | Karolinska Institutet | Glaucoma Research Foundation | $0.05 | 3/14/2023 |
| NMDP to award University of Texas funding to evaluate a therapeutic for dysbiotic microbiota induced intestinal graft-versus-host disease | MD Anderson Cancer Center | National Marrow Donor Program | Payment unspecified | 3/16/2023 |
| NIDA to award Icahn School of Medicine funding to identify a molecule and signaling pathway in the brain | Mount Sinai Medical Center, Miami | National Institute on Drug Abuse | Payment unspecified | 3/7/2023 |
| Murdoch Children's Research Institute to receive funding from Medical Research Future Fund for research into genetic heart disease | Murdoch Childrens Research Institute | Australian Government | $0.73 | 3/16/2023 |
| MJFF to award research funding to Olatec Therapeutics to evaluate Dapansutrile in animal models of parkinson’s disease | Olatec Therapeutics LLC | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 3/10/2023 |
| Vinnova to award Oncopeptides funding to develop peptide drug conjugate-based treatment options for glioblastoma | Oncopeptides AB | Vinnova | $0.28 | 3/28/2023 |
| BMGF to award Osivax funding for the development of OVX-836 against Influenza virus infection | Osivax SAS | Bill & Melinda Gates Foundation | $1.00 | 3/28/2023 |
| Glyconet to award Plantform funding to develop plant-based treatment for type II diabetes and obesity | Plantform Corp. | GlycoNet | Payment unspecified | 3/20/2023 |
| National Institute on Aging to award Praetego funding to develop PTG-630 for diabetic retinopathy | Praetego Inc. | National Institute on Aging | $0.30 | 3/2/2023 |
| National Research Council of Canada to award Rakovina Therapeutics funding to develop DNA-damage response inhibitors | Rakovina Therapeutics Inc. | National Research Council of Canada | $0.09 | 3/22/2023 |
| MJFF to award Selonterra funding for the development of clinical candidates against Parkinson's disease | Selonterra Inc. | The Michael J Fox Foundation for Parkinson's Research | $2.50 | 3/8/2023 |
| European Innovation Council to award Smart Immune funding to develop Protcell for cancers and infection | Smart Immune SAS | European Innovation Council | $2.70 | 3/30/2023 |
| BMGF to award Spybiotech funding to develop pan-SARS-CoV-2 and pan-sarbecovirus vaccines | Spybiotech Ltd. | Bill & Melinda Gates Foundation | $4.09 | 3/20/2023 |
| NMDP to award Stanford University funding to evaluate CAR-T cell therapy for blood and marrow transplant | Stanford University | National Marrow Donor Program | Payment unspecified | 3/16/2023 |
| CIRM to award Tachyon Therapeutics funding to support phase I clinical study of TACH-101 for advanced solid tumors and gastrointestinal cancers | Tachyon Therapeutics Inc. | California Institute for Regenerative Medicine | $7.10 | 3/1/2023 |
| Tetra Bio-Pharma to receive funding from NRC IRAP to develop ARDS-003 oral formulation for systemic hyperinflammation | Tetra Bio-Pharma Inc. | National Research Council of Canada | $0.15 | 3/3/2023 |
| Snow Medical Research Foundation to award The Macfarlane Burnet Institute funding to develop vaccines and therapeutics for malaria | The Macfarlane Burnet Institute for Medical Research and Public Health | Snow Medical Research Foundation | $0.66 | 3/28/2023 |
| Prostate Cancer Foundation to award University of Chicago funding to develop combination immunotherapy treatment for advanced prostate cancer | University of Chicago | Prostate Cancer Foundation | Payment unspecified | 3/2/2023 |
| NHGRI to award University of Miami Miller funding for Morphic program to determine the function of genes | University of Miami | National Human Genome Research Institute | $7.50 | 3/3/2023 |
| NIAID to award University of Miami funding to conduct a study on the vectored delivery of anti-HIV antibodies for mucosal protection against HIV | University of Miami Health System | National Institute of Allergy and Infectious Diseases | $3.00 | 3/28/2023 |
| NIA to award University of Miami funding to conduct phase IIb study for neflamapimod for Lewy body dementia | University of Miami Miller School of Medicine | National Institute on Aging | $21.00 | 3/13/2023 |
| Unravel Biosciences to receive funding from the Collaborative Center for X-linked Dystonia Parkinsonism at Massachusetts General Hospital to perform target discovery and validate drug candidates for the treatment of X-linked dystonia Parkinsonism | Unravel Biosciences Inc. | Collaborative Center for X-linked Dystonia Parkinsonism at Massachusetts General Hospital | Payment unspecified | 3/30/2023 |
| FARA to award Vesigen funding to evaluate the use of ARMMs technology for Friedreich's Ataxia | Vesigen Therapeutics Inc. | Friedreich's Ataxia Research Alliance | Payment unspecified | 3/14/2023 |
| GRF to award Washington University funding to conduct research on choroid resident T cells for ocular hypertensive injury | Washington University in St Louis | Glaucoma Research Foundation | $0.05 | 3/14/2023 |
| NINDS to award Aisa Pharma funding to study Profervia as a non-opioid analgesic for acute and chronic pain | Aisa Pharma Inc. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 4/3/2023 |
| EU Horizon to award Akthelia funding for IN-ARMOR project to combat antimicrobial resistance | Akthelia Pharmaceuticals ehf | EU Horizon 2020 | $6.44 | 4/17/2023 |
| Outram Bio to award Albatroz Therapeutics funding to develop therapeutic antibodies against cancerous solid tumors and arthritic cartilage degradation | Albatroz Therapeutics | Outram Bio Pte. Ltd. | $3.00 | 4/25/2023 |
| Innosuisse to award Aldena Therapeutics and Empa funding to develop microneedle particles as a skin delivery system | Aldena Therapeutics Inc. and Empa | Innosuisse | $0.67 | 4/26/2023 |
| Cystic Fibrosis Foundation to award Anagram Therapeutics funding to support development of its enzyme replacement therapy | Anagram Therapeutics Inc. | Cystic Fibrosis Foundation | $15.50 | 4/5/2023 |
| MRFF to award AIBN funding to test gene therapies for children with hereditary spastic paraplegia | Australian Institute for Bioengineering and Nanotechnology | Australian Government Department of Health and Ageing | Payment unspecified | 4/5/2023 |
| CIRM to award Cedars-Sinai funding to develop pluripotent stem cell therapy against musculoskeletal injuries including torn tendons | Cedars-Sinai Medical Center | California Institute for Regenerative Medicine | $1.50 | 4/27/2023 |
| GFF to award CHOP funding for the critical neurofibromatosis research and to accelerate treatment for neurofibromatosis type 1 | Childrens Hospital of Philadelphia | The Gilbert Family Foundation | $10.00 | 4/4/2023 |
| JDRF to award Diamyd Medical funding to support the ongoing phase III study of Diamyd | Diamyd Medical AB | Juvenile Diabetes Research Foundation | $5.00 | 4/4/2023 |
| NCI to award Duo Oncology a grant to develop combination therapy for pancreatic cancer | Duo Oncology Inc. | National Cancer Institute | $2.00 | 4/17/2023 |
| Solve FSHD to invest in Epic Bio for the development of EPI-321 against facioscapulohumeral muscular dystrophy | Epicrispr Biotechnologies Inc. | Solve FSHD | Payment unspecified | 4/18/2023 |
| Cancer Institute to award GIMR grant to investigate the use of an antifungal medication to enhance the effectiveness of immunotherapy for pancreatic cancer | Garvan Institute of Medical Research | Cancer Institute New South Wales | Payment unspecified | 4/17/2023 |
| SWElife to award funding to Gedea Biotech to support the clinical trial of pHyph against vulvovaginal candida infections | Gedea Biotech AB | Swelife | $0.29 | 4/4/2023 |
| KFRM to award GI Cell funding to support the non-clinical research and phase I clinical approval of Drone Treg for inflammatory bowel disease | GI Cell Inc. | Korean Fund for Regenerative Medicine | $13.80 | 4/11/2023 |
| JDRF to award Humacyte funding to support the development and testing of the BVP therapeutic for type 1 diabetes | Humacyte Inc. | Juvenile Diabetes Research Foundation International | Payment unspecified | 4/27/2023 |
| CIRM to award Kala Pharmaceuticals funding to support ongoing KPI-012 program for the treatment of persistent corneal epithelial defect | Kala Pharmaceuticals Inc. | California Institute for Regenerative Medicine | $15.00 | 4/28/2023 |
| LRA to award URMC funding to investigate SGLT2 inhibitors for type II diabetes | Lupus Research Alliance Inc. | University of Rochester Medical Center | $0.60 | 4/20/2023 |
| Innovate UK to award Maxion Therapeutics funding to use Knotbody platform to develop antibodies to treat autoimmune diseases | Maxion Therapeutics Ltd. | Innovate UK | $2.50 | 4/19/2023 |
| NIA to award HRI funding to conduct a study on reduction of benzodiazepine medications use related to insomnia and anxiety | National College of Natural Medicine | National Institute on Aging | $0.16 | 4/7/2023 |
| National Institute of Neurological Disorders and Stroke to award Nuvox Pharma funding to support preclinical development of NanO2 as a cerebroprotectant for ischemic stroke | Nuvox Pharma LLC | National Institute of Neurological Disorders and Stroke | $0.90 | 4/25/2023 |
| National Institute on Drug Abuse to award Omeros funding to develop for OMS-527 for cocaine use disorder | Omeros Corp. | National Institute on Drug Abuse | $6.69 | 4/10/2023 |
| CIRM to award Ossium Health funding to support the development of OSSM-007 for steroid-refractory acute graft versus host disease | Ossium Health Inc. | California Institute for Regenerative Medicine | $3.46 | 4/28/2023 |
| NIH to award Rise Therapeutics funding to develop a new therapeutic against acute respiratory distress syndrome | Rise Therapeutics LLC | National Institutes of Health | Payment unspecified | 4/13/2023 |
| Innovate UK to award Senisca funding to develop oligonucleotide therapeutics to treat idiopathic pulmonary fibrosis | Senisca Ltd. | Innovate UK | $0.69 | 4/20/2023 |
| National Institute of Neurological Disorders and Stroke to award Sinopia Biosciences funding to develop SB-0110 for Parkinson’s disease and levodopa-induced dyskinesia | Sinopia Biosciences Inc. | National Institute of Neurological Disorders and Stroke | $3.30 | 4/19/2023 |
| MJFF to award Sinopia Biosciences funding to develop SB-0110 for Parkinson’s disease and levodopa-induced dyskinesia | Sinopia Biosciences Inc. | The Michael J Fox Foundation for Parkinson's Research | $2.00 | 4/19/2023 |
| Bill & Melinda Gates Foundation awarded Smart Immune with an equity funding to develop SMART-101 to treat cancer and infectious disease | Smart Immune SAS | Bill & Melinda Gates Foundation | $5.00 | 4/17/2023 |
| Health Canada to award University Health Network funding to support the development of single-cell genomics technology for brain disease research | The University Health Network | Health Canada | $2.51 | 4/28/2023 |
| NIH to award Transcode Therapeutics funding to support the clinical evaluation of TTX-MC138 for the treatment of advanced solid tumors | Transcode Therapeutics Inc. | National Institutes of Health | $0.87 | 4/6/2023 |
| DoD to award Sylvester Comprehensive Cancer Center funding to support the study of immune responses to anti-CD19 CART-cell therapies to treat diffuse large B-Cell lymphoma | University of Miami Sylvester Comprehensive Cancer Center | U.S. Department of Defense | $1.50 | 4/7/2023 |
| MJFF to award Ventus Therapeutics funding to identify and develop small molecule therapeutics, NLRP3 PET Tracer against PD | Ventus Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $0.15 | 4/20/2023 |
| 7 Hills Pharma to receive funding from Cancer Prevention and Research Institute of Texas to develop 7HP-349 against cancer | 7 Hills Pharma LLC | Cancer Prevention and Research Institute of Texas | $13.50 | 5/22/2023 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases to award Amplo Biotechnology to develop AMP-201 for the treatment of severe congenital myasthenic syndrome caused by ColQ deficiency | Amplo Biotechnology Inc. | National Institute of Arthritis and Musculoskeletal and Skin Diseases | Payment unspecified | 5/30/2023 |
| NIH to award Aphios funding to develop double-encapsulated mRNA Vaccine against COVID-19 | Aphios Corp. | National Institutes of Health | Payment unspecified | 5/23/2023 |
| USAFA to award Appili Therapeutics funding to develop ATI-1701 for Francisella tularensis | Appili Therapeutics Inc. | United States Air Force Academy | $21.90 | 5/11/2023 |
| Innosuisse to award Araris Biotech funding to support the development of ADC candidates | Araris Biotech AG | Innosuisse Management AG | $2.70 | 5/5/2023 |
| VLAIO to award Astrivax funding to advance the vaccine platform to develop vaccines for various diseases | Astrivax NV | Flanders Innovation & Entrepreneurship | $2.68 | 5/30/2023 |
| National Multiple Sclerosis Society to award Clene Nanomedicine funding to support the phase II Repair-MS study of CNM-Au8 | Clene Nanomedicine Inc. | National Multiple Sclerosis Society | Payment unspecified | 5/25/2023 |
| Cancer Prevention & Research Institute of Texas to award CTMC funding to develop cell therapy | CTMC | National Resilience Inc. | $9.10 | 5/18/2023 |
| Merck Group to award Eurocine Vaccines funding to develop vaccine candidates | Eurocine Vaccines AB | Merck KGaA | $0.03 | 5/4/2023 |
| Swiss Innovation Agency to award Gain Therapeutics funding to advance the development of GT-02287 for patients with Parkinson’s disease caused by GBA1 mutations | Gain Therapeutics Inc. | Swiss Innovation Agency | $2.80 | 5/3/2023 |
| ERDF to award IFB Hamburg to study the safety and efficacy of new therapeutic candidates to treat COVID-19 | Hamburgische Investitions- und Forderbank | The European Union | $4.90 | 5/24/2023 |
| European Commission H2020 to award Iltoo Pharma funding to develop low dose interleukin-2 against amyotrophic lateral sclerosis | Iltoo Pharma | European Commission H2020 program | Payment unspecified | 5/12/2023 |
| Health Holland to award Ionctura funding to conduct preclinical investigation of IOA-359 for cancer | Ionctura SA | Health Holland | Payment unspecified | 5/3/2023 |
| BIRD Foundation to award Itolerance funding to develop iTOL-102 against type I diabetes | Itolerance Inc. | Binational Industrial Research and Development Foundation | $1.00 | 5/18/2023 |
| Bill & Melinda Gates Foundation to award Kallyope funding to identify bioactive compounds against enteric dysfunction | Kallyope Inc. | Bill & Melinda Gates Foundation | $8.20 | 5/10/2023 |
| Cystic Fibrosis Trust to award funding to LifeArc for the fast track treatment of lung infections | LifeArc | Cystic Fibrosis Trust | $18.22 | 5/11/2023 |
| US DoD to award Lumen Bioscience funding to develop and test a broad-spectrum, fast-acting intranasal powder for viral respiratory infections including influenza and COVID-19 | Lumen Bioscience Inc. | U.S. Department of Defense | $8.80 | 5/11/2023 |
| Brain Cancer Canada to award McMaster University funding to develop therapeutics against glioblastoma | McMaster University | Basotherm GmbH | $0.59 | 5/11/2023 |
| Break Through Cancer to award MD Anderson funding to support acute myeloid leukemia and clonal hematopoiesis research | MD Anderson Cancer Center | Break Through Cancer | $5.70 | 5/16/2023 |
| NIFA to award Medgene funding to develop and test vaccine against tickborne disease targets | Medgene Ltd. | U.S. Department of Agriculture | Payment unspecified | 5/22/2023 |
| BARDA to award Mediwound funding to develop Nexobrid biologic for eschar removal in severe burns | Mediwound Ltd. | Biomedical Advanced Research and Development Authority | $10.00 | 5/10/2023 |
| JDRF to award Minutia funding to develop subcutaneous transplants of insulin-producing cells and real-time monitoring platform for T1D | Minutia Inc. | Juvenile Diabetes Research Foundation Ltd | Payment unspecified | 5/24/2023 |
| CureDuchenne to award MyoGene funding to develop MyoDys45-55 for DMD | Myogene Bio LLC | CureDuchenne | Payment unspecified | 5/11/2023 |
| Multiple Myeloma Research Foundation to invest in Nectin Therapeutics to evaluate NTX-1088 against multiple myeloma | Nectin Therapeutics Ltd | Multiple Myeloma Research Foundation | Payment unspecified | 5/16/2023 |
| NIAID to award Novobiotic funding to develop new drugs for Candida auris imfection | Novobiotic Pharmaceuticals LLC | National Institute of Allergy and Infectious Diseases | $0.60 | 5/17/2023 |
| CPRIT to award Oncoresponse funding to support the advancement of OR-502 to treat cancer | Oncoresponse Inc. | Cancer Prevention and Research Institute of Texas | $13.00 | 5/18/2023 |
| Protinhi Therapeutics to receive funding from the European Innovation Council Accelerator to develop PTL-244 for the prevention of dengue infection | Protinhi Therapeutics BV | European Commission | $8.20 | 5/11/2023 |
| National Institute on Drug Abuse to award Siteone Therapeutics funding to develop STC-004 for acute and chronic pain conditions | Siteone Therapeutics Inc. | National Institute on Drug Abuse | $15.00 | 5/18/2023 |
| TFF Pharmaceuticals received additional undisclosed funding under the DARPA Personalized Protective Biosystems program through an ongoing subcontract with Leidos Holdings Inc. | TFF Pharmaceuticals Inc. | DARPA | Payment unspecified | 5/1/2023 |
| NCI to award Trethera funding to identify predictive biomarkers for TRE-515 in solid tumors | Trethera Corp. | National Cancer Institute | $2.00 | 5/30/2023 |
| NIDDKD to award University of Miami Miller School of Medicine funding to support the research for diabetic wound healing | University of Miami Miller School of Medicine | National Institute of Diabetes and Digestive and Kidney Diseases | $2.50 | 5/3/2023 |
| ACS-IRG to award Sylvester Comprehensive Cancer Center researchers funding to develop cancer therapies | University of Miami Sylvester Comprehensive Cancer Center | American Cancer Society Institutional Research | $0.26 | 5/18/2023 |
| Bill & Melinda Gates Foundation to award Vir Biotechnology funding to support a phase I study of VIR-1388 for the prevention of HIV infection | Vir Biotechnology Inc. | Bill & Melinda Gates Foundation | $10.00 | 5/2/2023 |
| MRFF to award WEHI funding to develop dendritic cancer vaccine | Walter and Eliza Hall Institute of Medical Research | Australian Government | $0.90 | 5/11/2023 |
| Gateway for Cancer Research to award Washington University School funding to develop vaccine against small cell lung cancer | Washington University School of Medicine in St Louis | Gateway for Cancer Research | $0.34 | 5/3/2023 |
| Cureator to award Xcystence Bio funding to advance research to develop new therapeutics for Polycystic Kidney Disease | Xcystence Bio Pty Ltd. | Cureator | Payment unspecified | 5/30/2023 |
| Bill & Melinda Gates Foundation to award Aegis Life funding to support the development of Fusogenix PLV platform for the delivery of DNA-encoded monoclonal antibodies as treatments for infectious diseases such as HIV, influenza and malaria | Aegis Life Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 6/7/2023 |
| Army Medical Research and Material Command to award Alpha Cognition funding to support a preclinical study of ALPHA-1062 as intranasal treatment to reduce functional deficit and brain abnormalities in patients with mild traumatic brain injuries due to blasts | Alpha Cognition Inc. | Army Medical Research and Material Command | $0.75 | 6/7/2023 |
| National Heart, Lung and Blood Institute to award Ambulero funding to develop E-selectin/AAV gene therapies to treat arterial occlusive diseases | Ambulero Inc. | National Heart, Lung and Blood Institute | Payment unspecified | 6/12/2023 |
| NMIN to award Asep Medical funding for preclinical study of nanoparticle peptide solution against sinus infections | Asep Medical Holdings Inc. | Nanomedicines Innovation Network | $0.15 | 6/23/2023 |
| The Michael J. Fox Foundation for Parkinson’s Research to award Axial Therapeutics funding to support the development of AX-5006 | Axial Therapeutics Inc. | The Michael J. Fox Foundation | Payment unspecified | 6/20/2023 |
| CEPI to award Celestial funding to support preclinical study of self-adjuvanting mRNA vaccine platform for Chikungunya | Celestial Therapeutics Inc. | Coalition for Epidemic Preparedness Innovations | $0.71 | 6/13/2023 |
| U.S. Department of Defense to award Cerus funding to develop pathogen reduced, lyophilized cryoprecipitate to treat bleeding due to trauma | Cerus Corp. | U.S. Department of Defense | $8.70 | 6/5/2023 |
| Pediatric Cancer Foundation to award Children's Hospital of Philadelphia funding to conduct clinical trial against pediatric leukemias | Childrens Hospital of Philadelphia | Pediatric Cancer Foundation | $1.00 | 6/28/2023 |
| Pew Charitable Trusts to award Cincinnati Children's Hospital Medical Center funding to determine immune-cell infiltration against eosinophilic esophagitis | Cincinnati Children's Hospital Medical Center | The Pew Charitable Trusts | Payment unspecified | 6/13/2023 |
| National Cancer Institute to award City of Hope funding to conduct phase II studies of Triplex for cytomegalovirus infection | City of Hope | National Cancer Institute | $3.22 | 6/15/2023 |
| National Institute on Alcohol Abuse and Alcoholism to award DMK Pharmaceuticals funding to support the development of a bifunctional small molecule for the treatment of alcohol use disorder | DMK Pharmaceuticals Corp. | National Institute on Alcohol Abuse and Alcoholism | Payment unspecified | 6/26/2023 |
| CIRM to award Eureka funding to conduct ARYA-2 phase I study of ET-140203 for r/r liver cancer, including HB, HCN-NOS, and HCC | Eureka Therapeutics Inc | California Institute for Regenerative Medicine | $10.60 | 6/6/2023 |
| Open Philanthropy to award Evotec funding to develop RNA-targeting small molecules against Henipaviruses | Evotec SE | Open Philanthropy Project | $1.70 | 6/2/2023 |
| VLAIO to award Exevir Bio funding for the preclinical research of XVR-021 against dengue | Exevir Bio BV | Flanders Innovation & Entrepreneurship | $1.72 | 6/28/2023 |
| VLAIO to award Flamingo Therapeutics funding to study danvatirsen in phase II in head and neck squamous cell carcinoma | Flamingo Therapeutics BV | Flanders Innovation & Entrepreneurship | $1.82 | 6/15/2023 |
| V Foundation for Cancer Research to award Fred Hutchinson Cancer Center funding to study the targeting CDK7 enzyme in pancreatic ductal adenocarcinoma | Fred Hutchinson Cancer Research Center | V Foundation for Cancer Research | $0.80 | 6/27/2023 |
| Bill & Melinda Gates Foundation to award GSK funding to develop M-72 against tuberculosis | GSK Plc | Bill & Melinda Gates Foundation | $400.00 | 6/28/2023 |
| Wellcome to award GSK funding to develop M-72 against tuberculosis | GSK Plc | Wellcome | $150.00 | 6/28/2023 |
| Walloon Region to award Hyloris Pharmaceuticals funding for the development of HY-083 against idiopathic rhinitis | Hyloris Pharmaceuticals SA | Walloon Region of Belgium Government | $1.07 | 6/8/2023 |
| Pew Charitable Trusts to award Johns Hopkins University funding to determine the activity of MEG3 gene regulator associated to aortic aneurysms | Johns Hopkins University | The Pew Charitable Trusts | Payment unspecified | 6/13/2023 |
| ItsME Foundation to award Karolinska Institutet funding to develop therapeutics against meningitis and encephalitis | Karolinska Institutet | ItsME Foundation | Payment unspecified | 6/22/2023 |
| National Institutes of Health to award Kintara Therapeutics funding to develop REM-001 against CMBC | Kintara Therapeutics Inc. | National Institutes of Health | $2.00 | 6/28/2023 |
| NIH to award Marker Therapeutics funding to develop MT-401 for the treatment of patients with acute myeloid leukemia after hematopoietic stem cell transplant | Marker Therapeutics Inc. | National Institute of Health | $2.00 | 6/27/2023 |
| CBCF to award Monash University funding to discover therapies against brain cancer | Monash University | Cure Brain Cancer Foundation | Payment unspecified | 6/30/2023 |
| Steven & Alexandra Cohen Foundation to award MAPS funding to support the development of MDMA and psychedelic assisted therapies for Post traumatic stress disorder | Multidisciplinary Association for Psychedelic Studies Inc | Steven & Alexandra Cohen Foundation | $5.00 | 6/22/2023 |
| Wings for Life to award Nervgen funding to support phase Ib/IIa clinical study of NVG-291 for spinal cord injury | Nervgen Pharma Corp. | Wings for Life | $3.18 | 6/27/2023 |
| UK Ministry of Defence to award NHSBT funding for dry plasma project to treat injured soldiers on the battlefield | NHS Blood & Transplant | UK Ministry of Defence | $5.95 | 6/14/2023 |
| CQDM to award Oragenics funding to develop a variant-agnostic COVID-19 protein antigen for use in NT-CoV2-1 against COVID-19 variants | Oragenics Inc. | CQDM | Payment unspecified | 6/5/2023 |
| Bpifrance to award OSE Immunotherapeutics funding to develop a companion diagnostic for Tedopi vaccine against NSCLC | OSE Immunotherapeutics SA | EPIC Bpifrance | $1.61 | 6/20/2023 |
| KDDF to award Spark funding for the development of SBP-401 against idiopathic pulmonary fibrosis | Spark Biopharma Inc. | Korea Drug Development Fund | Payment unspecified | 6/30/2023 |
| Pancreatic Cancer North America to award SU2C funding to support vaccine research against pancreatic cancer | Stand Up To Cancer | Pancreatic Cancer North America | $1.50 | 6/1/2023 |
| Pew Charitable Trusts to award Stanford University funding to develop vaccine candidates against COVID-19 | Stanford University | The Pew Charitable Trusts | Payment unspecified | 6/13/2023 |
| National Institute of Allergy and Infectious Diseases to award TFF Pharmaceuticals funding to develop pan-flu multivariant mucosal vaccine using thin film freezing technology | TFF Pharmaceuticals Inc. | National Institute of Allergy and Infectious Diseases | $2.97 | 6/26/2023 |
| Imagio consortium to award Thermosome funding to develop magnet resonance-high intensity focused ultrasound enabled therapies for sarcoma | Thermosome GmbH | Imagio consortium | $1.40 | 6/20/2023 |
| NCI to award Thetis SBIR grant to develop TP-317 against pancreatic cancer | Thetis Pharmaceuticals LLC | National Cancer Institute | $2.40 | 6/2/2023 |
| NIAID to award Trethera STTR funding for the IND enabling activities of TRE-515 against systemic lupus erythematosus | Trethera Corp. | National Institute of Allergy and Infectious Diseases | $0.60 | 6/27/2023 |
| V Foundation for Cancer Research to award Helen Diller Family Comprehensive Cancer Center funding to study cutting-edge CART-T cells against gastrointestinal malignancies | UCSF Helen Diller Family Comprehensive Cancer Center | V Foundation for Cancer Research | $0.80 | 6/27/2023 |
| CEPI to grant Leipzig University to expand the use of artificial intelligence in the creation of vaccines against diseases with the potential to become pandemic | Universität Leipzig | Coalition for Epidemic Preparedness Innovations | $1.90 | 6/5/2023 |
| Canadian Institutes of Health Research to award University of Calgary to study the mechanisms of psilocybin-assisted psychotherapy to treat alcohol use disorder | University of Calgary | Canadian Institutes of Health Research | $1.00 | 6/29/2023 |
| CureDuchenne to award University of Florida funding to study Vyvgart against Duchenne dystrophy | University of Florida | CureDuchenne | $1.00 | 6/15/2023 |
| CureDuchenne, MDA and PPMD to award UF funding to conduct phase II clinical study of vyvgart to lower AAV antibodies precluding Duchenne dystrophy patients from gene therapy | University of Florida | Muscular Dystrophy Association Inc. | $0.30 | 6/15/2023 |
| Parent Project Muscular Dystrophy to award University of Florida funding to assess the safety and efficacy of efgartigimod alfa-fcab in DMD | University of Florida | Parent Project Muscular Dystrophy | $0.10 | 6/15/2023 |
| Leukemia & Lymphoma Society to award University of Miami Health System funding to study Immune based therapeutics against multiple myeloma | University of Miami Health System | The Leukemia & Lymphoma Society | $0.75 | 6/13/2023 |
| NCC to award University of Nebraska Medical Center funding to develop an NTSR1-targeted radiotherapeutic for colorectal cancer and other NTSR1-positive cancers | University of Nebraska Medical Center | National Cancer Center Inc | $0.05 | 6/29/2023 |
| V Foundation for Cancer Research to award University of New Mexico Cancer Research funding to study biomarker for immune therapy in ovarian cancer | University of New Mexico Cancer Research & Treatment Center | V Foundation for Cancer Research | $0.80 | 6/27/2023 |
| Australian Research Council to award University of Queensland funding to study Nuvec nanoparticles for the delivery of mRNA | University of Queensland | Australian Research Council | $0.40 | 6/27/2023 |
| NIHR to award University of Sheffield funding to support EXPERTS-ALS clinical study for amyotrophic lateral sclerosis | University of Sheffield | National Institute for Health Research | $5.71 | 6/21/2023 |
| National Cancer Institute to award University of Tennessee Health Science Center funding to develop oncology therapeutics | University of Tennessee Health Science Center | National Cancer Institute | $3.07 | 6/21/2023 |
| U.S. Department of Defense to award University of Tennessee Health Science Center funding to develop oncology therapeutics | University of Tennessee Health Science Center | U.S. Department of Defense | $0.92 | 6/21/2023 |
| US DoD to award UTHealth funding to evaluate the effects of HB-adMSCs in reducing chronic neuroinflammatory response to severe traumatic brain injury | University of Texas Health Science Center Houston | U.S. Department of Defense | $5.00 | 6/1/2023 |
| Canadian Institutes of Health Research to award University of Toronto to study PEARL therapy for patients with advanced cancer | University of Toronto | Canadian Institutes of Health Research | $1.93 | 6/29/2023 |
| Innovate UK to award Vaxequity funding to advance the manufacturing process for RNA vaccines and therapeutics | Vaxequity Ltd. | Innovate UK | $0.85 | 6/5/2023 |
| CBCF to award Walter and Eliza Hall Medical Institute funding to discover therapies against brain cancer | Walter and Eliza Hall Institute of Medical Research | Cure Brain Cancer Foundation | Payment unspecified | 6/30/2023 |
| Leona M. and Harry B. Helmsley to award Weill Cornell Medicine funding to support clinical study of antifungal drugs in Crohn’s disease | Weill Cornell Medicine | Leona M and Harry B Helmsley Charitable Trust | $1.90 | 6/15/2023 |
| JDRF to award Zucara Therapeutics funding to support planned phase IIa study of the effect of ZT-01 on nocturnal hypoglycemia events in type 1 diabetes | Zucara Therapeutics Inc. | JDRF | $2.00 | 6/23/2023 |
| NIH to award Advent Therapeutics funding for neonatal lung therapy | Advent Therapeutics Inc. | National Institutes of Health | $6.00 | 7/18/2023 |
| Solve FSHD to award Altay funding to investigate the effects of STAT3 inhibitors on muscle pathology and fibrosis in a preclinical model of FSHD | Altay Therapeutics Inc. | Solve FSHD | Payment unspecified | 7/11/2023 |
| U.S. government to award Apogee Biotechnology funding to support development of opaganib as a medical countermeasure for gastrointestinal acute radiation syndrome | Apogee Biotechnology Corp. | U.S. government | $1.70 | 7/24/2023 |
| NIAID to award Applied Biomath funding to develop a simulation platform for Immunocytokines | Applied Biomath LLC | National Institute of Allergy and Infectious Diseases | $0.30 | 7/27/2023 |
| National Eye Institute to award Caeregen Therapeutics funding to develop CTR-107 (Noregen) for the treatment of retinal-related vision loss due to a wide range of inherited and age-related diseases | Caeregen Therapeutics LLC | National Eye Institute | $1.40 | 7/17/2023 |
| Medical research agency to award Captor therapeutics funding to develop small molecule against colorectal cancer | Captor Therapeutics Inc. | Agencja Bada? Medycznych | $18.00 | 7/18/2023 |
| European Innovation Council to award Celtic Biotech funding to develop CB-24 for cancer | Celtic Biotech Ltd. | European Innovation Council | $2.80 | 7/18/2023 |
| JRPFF to award Craig Hospital funding to conduct R&D to provide care to people who have sustained a SCI or brain injury | Craig Hospital | Jay and Rose Phillips Family Foundation | $1.50 | 7/25/2023 |
| Solve FSHD to award Cytokinetics finding to develop FSTAs for facioscapulohumeral muscular dystrophy | Cytokinetics Inc. | Solve FSHD | Payment unspecified | 7/11/2023 |
| NICHD to award Dare Bioscience funding to support the proof-of-concept studies of a therapeutic for idiopathic preterm birth | Daré Bioscience Inc. | Eunice Kennedy Shriver National Institute of Child Health & Human Development | $0.38 | 7/31/2023 |
| EIC to award Elgan Pharma funding to support phase III study of ELGN-GI against intestinal malabsorption in preterm Infants | Elgan Pharma Ltd. | European Commission | $2.50 | 7/19/2023 |
| European Commission to award Genecode funding to develop therapies against Parkinson's disease | Genecode AS | European Commission | $1.84 | 7/6/2023 |
| Solve GNE to award Gradalis funding for clinical study of GNE- Lipoplex against hereditary inclusion body myopathy-2 | Gradalis Inc. | SolveGNE | Payment unspecified | 7/31/2023 |
| CEPI to grant HMRI led consortium to advance the use of AI to analyze the structures of viruses that are likely to cause the next outbreak of Disease X | Houston Methodist Research Institute | Coalition for Epidemic Preparedness Innovations | $4.98 | 7/18/2023 |
| German government to award IAVI funding to develop Mycobacterium tuberculosis vaccine | International AIDS Vaccine Initiative | German Federal Ministry of Education and Research | $10.01 | 7/6/2023 |
| NIAID to award Johns Hopkins University funding to study effects of phenotypes in post treatment Lyme disease | Johns Hopkins University | National Institute of Allergy and Infectious Diseases | Payment unspecified | 7/21/2023 |
| U.S. Department of Defense to award Just - Evotec Biologics contract for the development of monoclonal antibodies targeting orthopoxviruses | Just - Evotec Biologics Inc. | U.S. Department of Defense | $74.00 | 7/5/2023 |
| Swedish Brain Foundation to award Karolinska Institutet funding to develop treatments against cluster headache | Karolinska Institutet | Hjärnfonden | Payment unspecified | 7/6/2023 |
| Swedish Research Council to award Karolinska University Hospital funding to study of Montelukast Versafilm for the treatment of Parkinson’s disease | Karolinska University Hospital | Swedish Research Council | $2.00 | 7/25/2023 |
| Kayothera to receive funding from National Institutes of Health to develop therapeutics for diabetes and oncology | Kayothera Inc. | National Institutes of Health | $0.70 | 7/19/2023 |
| Adamis Pharmaceuticals to fund LUMC for the ZIMHI clinical study against narcotic overdose | Leiden University Medical Center | Adamis Pharmaceuticals Corp. | Payment unspecified | 7/28/2023 |
| BARDA to award Melinta Therapeutics funding to test Baxdela (delafloxacin) and Vabomere (meropenem and vaborbactam) as potential treatments for use in pediatric patients and against biothreat pathogens | Melinta Therapeutics LLC | Biomedical Advanced Research and Development Authority | $141.90 | 7/10/2023 |
| Innovate UK to award NK:IO funding for development of NK cell therapy | NK:IO Ltd. | Innovate UK | $2.10 | 7/11/2023 |
| Michael J. Fox Foundation to award Nysnobio funding to advance the development of NB-001 in Parkinsons disease | Nysnobio GT LLC | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 7/17/2023 |
| NIAID to fund Pluri to advance development of PLX-R18 for hematopoietic acute radiation syndrome | Pluri Inc. | National Institute of Allergy and Infectious Diseases | $4.20 | 7/11/2023 |
| NIA to award RFU funding to investigate the relation between the onset of Alzheimer's disease in individuals with Down syndrome | Rosalind Franklin University of Medicine & Science | National Institutes of Health | $2.40 | 7/25/2023 |
| Medical Research Agency to award Ryvu Therapeutics funding for the phase II study of for RVU-120 in combination with Venetoclax against acute myelogenous leukemia | Ryvu Therapeutics | Agencja Bada? Medycznych | $15.57 | 7/31/2023 |
| Alabama State Legislature to award University of Alabama funding to support the TSC research program | University of Alabama at Birmingham | Alabama Legislature | Payment unspecified | 7/13/2023 |
| NIHR to award University of Bristol funding to conduct a study on antibiotics against urinary tract infection | University of Bristol | National Institute for Health and Care Research | $3.75 | 7/21/2023 |
| Solve FSHD to award funding to University of British Columbia to conduct research and develop therapeutics for Facioscapulohumeral muscular dystrophy | University of British Columbia | Solve FSHD | $0.35 | 7/11/2023 |
| FSR to award University of Illinois funding to conduct research and develop therapies against sarcoidosis | University of Illinois | Foundation for Sarcoidosis Research | $0.15 | 7/25/2023 |
| NIH to award University of Miami funding to conduct a clinical study on buprenorphine to reduce overdose opioid deaths | University of Miami Miller School of Medicine | National Institutes of Health | $14.20 | 7/25/2023 |
| ACRF to award CAI to support the development new alpha therapies against cancer | University of Queensland | Australian Cancer Research Foundation | $1.20 | 7/17/2023 |
| NIAID to award Virginia Tech funding to conduct research on peptidoglycan fragments against Lyme disease | Virginia Polytechnic Institute and State University | National Institutes of Health | Payment unspecified | 7/21/2023 |
| DTRA to award Vitrivax funding to develop a Burkholderia pseudomallei single injection vaccine for melioidosis and glanders | Vitrivax Inc. | Defense Threat Reduction Agency | $29.00 | 7/19/2023 |
| Bill & Melinda Gates Foundation to award 4basebio funding to advance the development program of thermostable nucleic acid-based vaccines | 4basebio plc | Bill & Melinda Gates Foundation | Payment unspecified | 8/2/2023 |
| NIAID to award AAHI funding to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus | Access to Advanced Health Institute | National Institute of Allergy and Infectious Diseases | $18.00 | 8/3/2023 |
| BARDA to award Allucent funding to advance clinical research and development of COVID-19 booster vaccines | Allucent | Biomedical Advanced Research and Development Authority | Payment unspecified | 8/28/2023 |
| NIH to award Amygdala Neurosciences funding to support IND-enabling studies of ANS-858 for patients being treated for alcohol and other substance use disorders | Amygdala Neurosciences Inc. | National Institutes of Health | $2.00 | 8/3/2023 |
| BARDA to award Bavarian Nordic funding for the manufacturing of new bulk product for the smallpox/mpox vaccine | Bavarian Nordic A/S | Biomedical Advanced Research and Development Authority | $120.00 | 8/3/2023 |
| NIH to award BITT funding for advancement of BITT-101 for use in Sjogren’s syndrome | Boston Immune Technologies & Therapeutics Inc. | National Institutes of Health | Payment unspecified | 8/31/2023 |
| NCI to award grant to Briacell to develop Bria-OTS, off-the-shelf personalized immuno therapeutics for cancer | Briacell Therapeutics Corp. | National Cancer Institute | Payment unspecified | 8/16/2023 |
| Kenyon Foundation to award Centenary Institute funding to support CAR-T cell therapy research | Centenary Institute Cancer Medicine & Cell Biology | Kenyon Foundation | $0.02 | 8/4/2023 |
| National Institute of Allergy and Infectious Diseases to award Ceramedix funding to evaluate the non-clinical pharmacology of anti-ceramide antibodies to mitigate and/or treat illness due to radiation exposure | Ceramedix Holding LLC | National Institute of Allergy and Infectious Diseases | $3.00 | 8/24/2023 |
| CIRM to award City of Hope funding to support three phase I clinical studies of cell and gene therapies for HIV, AML and severe aplastic anemia | City of Hope | California Institute of Regenerative Medicine | $32.30 | 8/9/2023 |
| Government of Canada to award CARB-X funding to develop new projects to prevent diagnose and treatment drug-resistant infections against antimicrobial resistance | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | Federal Government of Canada | $6.30 | 8/3/2023 |
| UK Government to award CARB-X funding to support the early development of products for the prevention, diagnosis and treatment of drug-resistant bacterial infections | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | UK Government | $30.04 | 8/10/2023 |
| PanCAN to award Dana-Farber Cancer Institute funding to conduct research for pancreatic cancer | Dana-Farber Cancer Institute Inc. | Pancreatic Cancer Action Network US | $4.00 | 8/30/2023 |
| U.S. Biomedical Advanced Research and Development Authority to award Emergent Biosolutions contract for development, manufacturing scale-up and procurement of Ebanga for Ebola virus disease | Emergent Biosolutions Inc. | Biomedical Advanced Research and Development Authority | $704.00 | 8/1/2023 |
| Nico to award Emory University funding to research on organoid formation and cultures for brain tumor | Emory University | Nico Corp. | $0.07 | 8/21/2023 |
| U.S. Department of Defense to award Ena Respiratory funding to develop INNA-051 for the prevention of complications associated with respiratory viral infections | Ena Respiratory Pty Ltd. | U.S. Department of Defense | $3.80 | 8/29/2023 |
| NIAID to award Exavir funding to support the development of XVIR-110 for HIV infection | Exavir Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $3.00 | 8/22/2023 |
| Alzheimer's Research UK to award University of Exeter funding to support research on dementia and Alzheimer’s disease | Exeter University | Alzheimer's Research UK | $0.46 | 8/1/2023 |
| CEPI to award Gennova Biopharmaceuticals funding to develop self-amplifying mRNA platform for vaccine candidates against disease X | Gennova Biopharmaceuticals Ltd. | Coalition for Epidemic Preparedness Innovations | $7.20 | 8/8/2023 |
| Solve GNE to award Genosera a funding to develop bicistronic AAV gene therapy against GNE myopathy or hereditary inclusion body myopathy | Genosera Inc. | Solve GNE LLC | Payment unspecified | 8/14/2023 |
| ALS Association to award Harvard Medical School funding to identify gene fusion in amyotrophic lateral sclerosis patients | Harvard Medical School | The Amyotrophic Lateral Sclerosis Association | Payment unspecified | 8/17/2023 |
| KDDF to invest HK inno to identify epidermal growth factor receptor inhibitor combination with standard therapies against non-small-cell lung cancer | HK inno.N Corp. | Korea Drug Development Fund | Payment unspecified | 8/21/2023 |
| Federal Government to award a contract to Ihealth Labs for the manufacture of COVID-19 at-home test kits | Ihealth Labs Inc. | U.S. Government | Payment unspecified | 8/16/2023 |
| KDDF to award JW Pharmaceutical funding to develop JW-0061 for alopecia | JW Pharmaceutical Corp. | Korea Drug Development Fund | Payment unspecified | 8/28/2023 |
| Dioraphte to award Karolinska Institutet grant to conduct research and develop treatments against PKDL and leprosy | Karolinska Institutet | Dioraphte Foundation | $0.93 | 8/18/2023 |
| National Institute of Aging to award Neuronascent funding to develop NNI-362 for Alzheimer’s disease | Neuronascent Inc. | National Institute of Aging | Payment unspecified | 8/22/2023 |
| NIH’s NIMH to grant Psychogenics to use artificial intelligence to design novel medications for mental health diseases | Psychogenics Inc. | The National Institute of Mental Health | $1.00 | 8/15/2023 |
| DoD to award Puretech funding to conduct a phase II clinical trial of LYT-300 for Fragile X-associated tremor ataxia syndrome | Puretech Health plc | U.S. Department of Defense | $11.40 | 8/1/2023 |
| BARDA to award Regeneron Pharmaceuticals funding to develop next-generation COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection | Regeneron Pharmaceuticals Inc. | Biomedical Advanced Research and Development Authority | $326.00 | 8/23/2023 |
| NSF to award Remedium Bio funding to develop the Prometheus dose-adjustable gene therapy platform technology for the treatment of type 2 diabetes and obesity | Remedium Bio Inc. | National Science Foundation | Payment unspecified | 8/1/2023 |
| Wellcome to award SK bioscience grant to develop needle free patch delivery of NBP-618 typhoid vaccine | SK Bioscience Co. Ltd. | Wellcome | $3.61 | 8/23/2023 |
| NIDA to award Sparian Bioscience funding to develop SBS-518 for stimulant use disorder | Sparian Biosciences Inc. | National Institute on Drug Abuse | $19.00 | 8/8/2023 |
| The Michael J. Fox Foundation to award Stealth Biotherapeutics funding to develop SBT-272 for Parkinson's disease | Stealth Biotherapeutics Inc. | The Michael J. Fox Foundation | Payment unspecified | 8/9/2023 |
| National Institute of Allergy and Infectious Diseases to award Trethera funding to develop TRE-515 for acute disseminated encephalomyelitis | Trethera Corp. | National Institute of Allergy and Infectious Diseases | $0.60 | 8/15/2023 |
| National Institute on Drug Abuse to award Tris Pharma funding to develop cebranopadol to prevent and treat opioid use disorder | Tris Pharma Inc. | National Institute on Drug Abuse | $16.60 | 8/28/2023 |
| ALS Association to award Ulm University Hospital funding to study CSF fluid in ALS linked genetic mutation | Universitätsklinikums Ulm | The Amyotrophic Lateral Sclerosis Association | Payment unspecified | 8/17/2023 |
| CEPI to award University of Oxford funding to develop prototype vaccines using ChAdOx platform against Disease X | University of Oxford | Coalition for Epidemic Preparedness Innovations | $80.00 | 8/29/2023 |
| Wellcome to award Vaxxas funding to conduct IND-enabling and clinical studies for SKYTyhpoid against typhoid | Vaxxas Pty Ltd. | Wellcome | $3.67 | 8/23/2023 |
| Eurostars to award consortium led by Addex Therapeutics funding to support metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator program for mild neurocognitive disorder | Addex Therapeutics Ltd. | Eurostars | $4.26 | 9/21/2023 |
| Bill & Melinda to award AN2 Therapeutics funding to discover, boron containing small molecules for the treatment of tuberculosis and malaria | An2 Therapeutics Inc | Bill & Melinda Gates Foundation Trust | Payment unspecified | 9/26/2023 |
| NIH to award Aphios with Phase I SBIR grant to develop a sustained release combination drug, APH-1501 with cannabidiol in biodegradable polymer nanospheres for chronic opioid use disorder relapse | Aphios Corp. | National Institutes of Health | Payment unspecified | 9/6/2023 |
| Alzheimer’s Drug Discovery Foundation to award Aprinoia Therapeutics funding to develop 18F-APN-1607 and its therapeutic, preclinical tau protein degraders | Aprinoia Therapeutics Inc. | Alzheimer’s Drug Discovery Foundation | $4.40 | 9/11/2023 |
| Arcturus Therapeutics extended agreement with the Cystic Fibrosis Foundation to increase its financial commitment to advance ARCT-032 | Arcturus Therapeutics Holdings Inc. | Cystic Fibrosis Foundation | $10.00 | 9/26/2023 |
| DTRA to award Armis Biopharma funding to develop Veriox DECON for battlefield wounds | Armis Biopharma Inc. | Defense Threat Reduction Agency | $20.30 | 9/28/2023 |
| CEPI to award Biontech funding to develop mRNA vaccines, including BNT-166 for monkeypox viral infection | Biontech SE | Coalition for Epidemic Preparedness Innovations | $90.00 | 9/18/2023 |
| US Department of Defense to award Cantargia grant to evaluate phase Ib/IIa clinical trial of nadunolimab against myelodysplastic syndrome or acute myeloid leukemia | Cantargia AB | US Department of Defense | $1.10 | 9/18/2023 |
| The Andy Hill Cancer research to award Deverra funding to develop CAR-NK and myeloid cell programs in hematologic malignancies and solid tumors | Deverra Therapeutics Inc. | Andy Hill CARE Fund | $3.50 | 9/11/2023 |
| GI Research Foundation to award Elicio Therapeutics funding to research two cancer vaccines, ELI-007 and ELI-008. | Elicio Therapeutics Inc. | GI Research Foundation | $2.60 | 9/7/2023 |
| JDRF to award Genedx funding to conduct the genomic screening and analysis against type 1 diabetes in newborns | Genedx LLC | Juvenile Diabetes Research Foundation Ltd. | Payment Unspecified | 9/20/2023 |
| NIH to award Golden Helix funding to study pharmacogenomics workflow for identifying biomarkers and treatment options | Golden Helix | National Institutes of Health | Payment unspecified | 9/26/2023 |
| BARDA to award a contract for Gritstone bio to conduct a phase IIb study of mRNA vaccine candidate against COVID-19 | Gritstone bio Inc. | Biomedical Advanced Research and Development Authority | $433.00 | 9/27/2023 |
| National Heart, Lung, and Blood Institute to award Hillhurst Biopharmaceuticals funding to develop HBI-002 for sickle cell disease | Hillhurst Biopharmaceuticals Inc. | National Heart, Lung, and Blood Institute | $3.00 | 9/21/2023 |
| AF to award Hospital for Special Surgery NY funding to conduct research and study on bone quality in ankle arthritis patients | Hospital for Special Surgery NY | Arthritis Foundation | $0.40 | 9/19/2023 |
| US Army DEVCOM to award Intron contract funding to develop bacteriophages against urinary tract infections, including uropathogenic Escherichia coli | Intron Biotechnology Inc. | U.S. Army Combat Capabilities Development Command Army Research Laboratory | Payment unspecified | 9/3/2023 |
| Austrian Research Promotion Agency to award InvIos funding to support phase Ib Palindrom study of APN-401 in patients with advanced and metastatic solid tumors | InvIos GmbH | Austrian Research Promotion Agency | Payment unspecified | 9/5/2023 |
| MSCRC to award Johns Hopkins University funding to research for human stem cell-based technologies | Johns Hopkins University | Maryland Stem Cell Research Commission | $0.48 | 9/20/2023 |
| Horizon Europe to award KI funding to conduct a clinical study on Epstein-Barr virus infected people developing multiple sclerosis | Karolinska Institutet | The European Union | $7.62 | 9/20/2023 |
| U.S. Department of Defense to award Mediwound to develop a temperature stable formulation of Nexobrid field-care burn treatment | Mediwound Ltd. | U.S. Department of Defense | $6.50 | 9/26/2023 |
| Foundation Fighting Blindness to award Mitochem Therapeutics funding to study MC-16's target and mechanism of action in retinal degeneration diseases | Mitochem Therapeutics Inc. | Foundation Fighting Blindness | $0.90 | 9/25/2023 |
| BARDA to award a contract for Modex to develop MSTAR multispecific antibodies against viral infectious diseases | Modex Therapeutics Inc. | Biomedical Advanced Research and Development Authority | $168.00 | 9/28/2023 |
| NIAID to award Mount Sinai grant to develop vaccines against multiple variants of coronaviruses | Mount Sinai School of Medicine | National Institute of Allergy and Infectious Diseases | $13.00 | 9/12/2023 |
| BARDA to award a contract to NTx to evaluate NTxscribe platform | Nature's Toolbox Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 9/7/2023 |
| MJFF to award Nine Square Therapeutics grant to advance development of parkin activators for the treatment of Parkinson’s disease | Nine Square Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $4.50 | 9/12/2023 |
| National Institutes of Health to award Omniose funding to develop vaccines against group B streptococcus | Omniose | National Institutes of Health | $3.00 | 9/27/2023 |
| Pancreatic Cancer Action Network to award Oncolytics Biotech funding to test combination of reovirus pelareorep in combination with modified Folfirinox chemotherapy with or without an immune checkpoint inhibitor for pancreatic cancer | Oncolytics Biotech Inc. | Pancreatic Cancer Action Network | $5.00 | 9/27/2023 |
| NHLBI to award Orange Grove Bio Phase II SBIR funding to advance the development of G-04 in the preservation of platelets for transfusion needs | Orange Grove Bio LLC | National Institutes of Health | $2.05 | 9/28/2023 |
| Innovate UK to award Pathios Therapeutics funding to develop small-molecule GPR65 inhibitors for treatment of malignant brain tumors | Pathios Therapeutics Ltd. | Innovate UK | $0.72 | 9/27/2023 |
| AAIM to award Paxxus funding to conduct proof of concept studies and to evaluate a methodology for aseptic presentation | Paxxus Inc. | Association for the Advancement of Medical Instrumentation (AAMI) | $0.01 | 9/19/2023 |
| KDDF to award Pinotbio funding to develop payloads for the ADC project | Pinotbio Inc | Korea Drug Development Fund | Payment unspecified | 9/25/2023 |
| NEI to award STTR grant to Proteris Biotech to develop Protearin for the treatment of ocular surface damage in epitheliopathy | Proteris Biotech Inc. | National Eye Institute | $0.29 | 9/19/2023 |
| Open Philanthropy to award Purdue university funding to conduct malaria drug trials | Purdue University | Open Philanthropy Project | $1.38 | 9/15/2023 |
| HS Chau Foundation to award Regel funding to develop modulate gene expression technology for next generation gene therapy against genetic disorders | Regel Therapeutics Inc. | HS Chau Foundation | $1.00 | 9/29/2023 |
| MSCRC to award Renovate Biosciences funding to develop human stem cell-based technologies and treatments | Renovate Biosciences Inc. | Maryland Stem Cell Research Commission | Payment unspecified | 9/20/2023 |
| NIAID to award ResVita Bio funding to develop RVB-101 against atopic dermatitis | Resvita Bio | National Institute of Allergy and Infectious Diseases | $0.25 | 9/18/2023 |
| BARDA to award Rho contract to provide statistical and data coordinating center services for phase II b clinical trials of COVID-19 vaccine candidates | Rho Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 9/25/2023 |
| GHIT Fund to award Sasakawa Health Foundation to conduct clinical trial of Lepvax against Leprosy | Sasagawa Memorial Health Foundation | Global Health Innovative Technology Fund | $1.00 | 9/27/2023 |
| JDRF to award Sidra Medicine funding to support type 1 diabetes autoantibody screening program | Sidra Medical & Research Center | Juvenile Diabetes Research Foundation Ltd. | $1.00 | 9/12/2023 |
| National Institute of Neurological Disorders and Stroke to award South Rampart Pharma funding to develop SRP-001 for acute and chronic pain | South Rampart Pharma Inc. | National Institute of Neurological Disorders and Stroke | $1.90 | 9/25/2023 |
| US DoD to award Spinogenix grant to support the development of SPG-302 against amyotrophic lateral sclerosis | Spinogenix Inc | U.S. Department of Defense | $1.00 | 9/26/2023 |
| National Institute on Aging to award Spinogenix funding to develop SPG-302 to regenerate synaptic connections in patients with Alzheimer’s disease and related neurodegenerative disorders | Spinogenix Inc. | National Institute on Aging | $3.00 | 9/12/2023 |
| NIH to award Phase II SBIR grant to Strykagen to conduct IND enabling studies for S-969 against muscular dystrophies, cachexia and sarcopenia | Strykagen Corp. | National Institutes of Health | $1.95 | 9/15/2023 |
| QMIF to award TC Biopharm to evalaute the therapeutic effect of gamma-delta T cells for mucosal infections | TC Biopharm Ltd. | Queen Mary University of London | Payment unspecified | 9/5/2023 |
| MDA to award Tel Aviv University funding to support for a RNA treatment against amyotrophic lateral sclerosis | Tel Aviv University | Muscular Dystrophy Association Inc. | $0.30 | 9/13/2023 |
| U.S. Department of Defense to award Theradaptive funding to conduct phase I/II study of Osteoadapt regenerative therapeutic product for spine and trauma repair | Theradaptive Inc. | U.S. Department of Defense | $7.40 | 9/26/2023 |
| Innovate UK to award Theragenix funding to develop dry powder gene therapy for bone graft augmentation | Theragenix Ltd. | Innovate UK | $1.25 | 9/5/2023 |
| NIH to award Thymmune Therapeutics funding for the thymus rejuvenation project to restructure damaged or non-functional thymus tissue | Thymmune Therapeutics Inc. | National Institutes of Health | $37.00 | 9/29/2023 |
| NIDDK to award STTR grant to Trethera to conduct research on TRE-515 against Crohn’s disease | Trethera Corp | National Institute of Diabetes and Digestive and Kidney Diseases | $0.40 | 9/25/2023 |
| LLSC to award University of Montreal funding to conduct research and discover treatments for pediatric blood cancer | Universite De Montreal | The Leukemia & Lymphoma Society of Canada | $0.60 | 9/5/2023 |
| US DoD to award Universitry of North Carolina grant to evaluate Tonix's TNX-102 SL against adverse effects of acute trauma | University North Carolina, Chapel Hill | U.S. Department of Defense | $3.00 | 9/27/2023 |
| CEPI to fund UC Davis to advance a vaccine against Rift Valley fever virus into clinical trials | University of California Davis | Coalition for Epidemic Preparedness Innovations | $28.50 | 9/14/2023 |
| AF to award University of Colorado-Denver funding to conduct research on synovial transcriptome and proteome for ankle osteoarthritis | University of Colorado | Arthritis Foundation | $0.20 | 9/19/2023 |
| MSCRC to award University of Maryland funding to develop human stem cell-based technologies and treatments | University of Maryland | Maryland Stem Cell Research Commission | $0.60 | 9/20/2023 |
| MRC to award Newcastle University grant to research on MultiStem in machine perfusion prior to kidney transplantation | University of Newcastle | Medical Research Council | Payment unspecified | 9/6/2023 |
| Nico to award University of Pittsburgh Medical center grant to develop therapies against chordoma tumor | University of Pittsburgh Medical Center | Nico Corp. | $0.05 | 9/21/2023 |
| Muscular Dystrophy Association to award University of Zurich's funding to develop targets for pompe disease | University of Zurich | Muscular Dystrophy Association Inc. | $0.21 | 9/13/2023 |
| NCI to award WUSM SPORE grant to conduct research programs for the prevention and treatment of endometrial cancer | Washington University School of Medicine in St Louis | National Cancer Institute | $11.60 | 9/5/2023 |
| NCI to award Washington University funding to study immune responses to a cancer causing virus after organ transplantation in children | Washington University School of Medicine in St Louis | National Cancer Institute | $5.70 | 9/22/2023 |
| NICHHD to award Weill Cornell Medicine grant to develop sAC inhibitor against male contraception | Weill Cornell Medicine | Eunice Kennedy Shriver National Institute of Child Health & Human Development | $6.00 | 9/21/2023 |
| U.S. Department of Defense to award Yale University funding to study methylone against post-traumatic stress disorder | Yale University | U.S. Department of Defense | $1.00 | 9/21/2023 |
| NIH to award Actinium Pharmaceuticals funding to support study of lomab-ACT as a conditioning agent for lymphodepletion prior to treatment with a CAR T-cell therapy | Actinium Pharmaceuticals Inc. | National Institutes of Health | Payment unspecified | 10/4/2023 |
| NIAID to award Aligos Therapeutics contract to advance development of ALG-097558 against coronavirus infection | Aligos Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $8.50 | 10/3/2023 |
| JDRF to award Allarta funding to conduct preclinical studies on hydrogel platform and to develop therapies for type 1 diabetes | Allarta Life Science Inc. | Juvenile Diabetes Research Foundation Ltd. | $0.80 | 10/2/2023 |
| U.S. Air Force Academy to award Appili Therapeutics funding to develop ATI-1701 for the prevention of infection with Francisella tularensis | Appili Therapeutics Inc. | U.S. Air Force Academy | $6.60 | 10/25/2023 |
| Japanese Government to award Arcalis funding for the production of mRNA vaccines and therapeutics | Arcalis Inc. | Japanese Government | Payment unspecified | 10/4/2023 |
| HHS to award BioInfoExperts funding to provide genomic sequencing of COVID-19 | Bio Info Experts LLC | US Department of Health and Human Services | $4.00 | 10/13/2023 |
| Biomedical Advanced Research and Development Authority to award Bioaegis Therapeutics funding to advance gelsolin for the treatment of acute respiratory distress syndrome | Bioaegis Therapeutics Inc. | U.S. Biomedical Advanced Research and Development Authority | $20.00 | 10/17/2023 |
| American Lung Association to award Boston University funding to determine Omicron prefering to target the upper respiratory tract and treatments for the infection | Boston University | American Lung Association | Payment unspecified | 10/12/2023 |
| PolG Foundation to award Broad Institute of MIT funding to conduct research on a variant to develop a comprehensive dashboard and a saturation mutagenesis library for POLG | Broad Institute Inc. | PolG Foundation | Payment unspecified | 10/10/2023 |
| CSL to award Caen Normandie University Hospital funding to conduct research on nanoparticles targeting micro-thrombi against neurovascular diseases | Caen University Hospital | CSL Ltd. | $0.33 | 10/4/2023 |
| Bill & Melinda to award Cansino funding to support the development of CSB-017 against polio | Cansino Biologics Inc. | Bill & Melinda Gates Foundation Trust | Payment unspecified | 10/24/2023 |
| HHS to award Castlevax funding to develop vector based intranasal vaccine candidate for COVID-19 | Castlevax Inc. | US Department of Health and Human Services | $338.00 | 10/13/2023 |
| National Institute on Drug Abuse to award Cessation Therapeutics Drug Abuse funding to develop subcutaneous formulation of anti-fentanyl monoclonal antibody, CSX-1004 SQ | Cessation Therapeutics Inc. | National Institute on Drug Abuse | $14.80 | 10/18/2023 |
| NINDS to award Clene funding to develop CNM-Au8 for amyotrophic lateral sclerosis | Clene Inc. | National Institute of Neurological Disorders and Stroke | $45.10 | 10/5/2023 |
| BARDA to award a Codagenix' contract to conduct a phase IIb clinical study on Coviliv against COVID-19 | Codagenix Inc. | Biomedical Advanced Research and Development Authority | $399.00 | 10/3/2023 |
| U.S. Department of Defense to award Codagenix funding to develop Codavax-Denv for dengue | Codagenix Inc. | U.S. Department of Defense | $5.88 | 10/24/2023 |
| NIH to award Couragene funding to develop gene editing technology for genetic diseases | Couragene Inc. | National Institutes of Health | $40.00 | 10/11/2023 |
| Alzheimer’s Drug Discovery Foundation to award Curasen Therapeutics funding to advance CST-3056 for Alzheimer’s disease | Curasen Therapeutics Inc. | Alzheimer’s Drug Discovery Foundation | $5.80 | 10/9/2023 |
| MFCR to award Dana-Farber Cancer Institute funding to develop T cell-directed therapies for cancer | Dana-Farber Cancer Institute Inc | The Mark Foundation for Cancer Research | Payment unspecified | 10/17/2023 |
| Bayer to award funding to Dana-Farber Cancer Institute to conduct research on darolutamide against prostate cancer | Dana-Farber Cancer Institute Inc. | Bayer AG | $1.00 | 10/25/2023 |
| CEPI to award Emervax grant to advance circular RNA platform technology for development of vaccines against emerging viruses | Emervax Inc. | Coalition for Epidemic Preparedness Innovations | $2.15 | 10/25/2023 |
| The Leukemia & Lymphoma Society to award Enterome funding to conduct the phase II Sidney study of EO-2463 in indolent non-Hodgkin B-cell lymphoma | Enterome SA | The Leukemia & Lymphoma Society | $3.19 | 10/30/2023 |
| BARDA to award Esperovax funding to advance the development of an oral COVID-19 RNA Vaccine | Esperovax Inc. | Biomedical Advanced Research and Development Authority | $1.00 | 10/3/2023 |
| KWF Dutch Cancer Society to award Evgen Pharma funding to evaluate SFX-01 against glioblastoma | Evgen Pharma plc | KWF Kankerbestrijding | $1.20 | 10/26/2023 |
| BARDA to award Gen1e Lifesciences funding to develop Aspect for acute respiratory distress syndrome | Gen1e Lifesciences Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 10/24/2023 |
| U.S. Department of Defense to award Gigagen funding to develop synthetic human antibody treatments for treating botulinum neurotoxins | Gigagen Inc. | U.S. Department of Defense | Payment unspecified | 10/19/2023 |
| BARDA to award HDT Bio funding to develop HDT-201 for COVID-19 | HDT Bio | Biomedical Advanced Research and Development Authority | $1.00 | 10/4/2023 |
| National Heart, Lung and Blood Institute to award Humanetics funding to support a series of studies with BIO-300 for idiopathic pulmonary fibrosis | Humanetics Corp. | National Heart, Lung and Blood Institute | Payment unspecified | 10/25/2023 |
| NIH to award Integral Molecular funding to discover antibodies against multiple myeloma and other cancers | Integral Molecular Inc, | National Institutes of Health | $0.90 | 10/5/2023 |
| BioArctic to support Karolinska Institutet to identify the TDP-43 fluid biomarkers and to determine the treatment options for ALS | Karolinska Institutet | Bioarctic AB | Payment unspecified | 10/3/2023 |
| ERC to award KI funding to map how disturbances in the gut microbiome can lead to IBD and colorectal cancer | Karolinska Institutet | European Research Council | $10.88 | 10/26/2023 |
| JDRF to award KCL funding to support study on sotagliflozin against kidney and heart complications related to diabetes | King's College London | Juvenile Diabetes Research Foundation Ltd | $1.65 | 10/13/2023 |
| NIH to award L2P Research Phase I SBIR grant to support the study on a cell therapy approach against osteoarthritis | L2P Research LLC | National Institutes of Health | Payment unspecified | 10/27/2023 |
| Innovate UK to award Laverock Therapeutics grant to advance immune effector cell therapeutic program using GEiGS technology to treat cancer | Laverock Therapeutics Ltd. | Innovate UK | $0.70 | 10/30/2023 |
| International Rett Syndrome Foundation to award Lucy Therapeutics funding to support the discovery of a treatment for Rett syndrome | Lucy Therapeutics Inc. | International Rett Syndrome Foundation | Payment unspecified | 10/11/2023 |
| DoD to award Lumen Bioscience funding to advance LMN-201 into the late stage trials against Clostridium difficile infection | Lumen Bioscience Inc. | US Department of Defense | $16.20 | 10/17/2023 |
| SkatteFUNN to award Lytix Biopharma funding to evaluate LTX-315 against advanced melanoma | Lytix Biopharma AS | Skattefunn | $1.30 | 10/17/2023 |
| The Mark Foundation to award MSKCC funding to conduct research on senescence biology and discover therapeutics against cancer | Memorial Sloan Kettering Cancer Center | The Mark Foundation for Cancer Research | Payment unspecified | 10/17/2023 |
| NIH to award University of Montana contract to develop vaccine adjuvant for use in a tuberculosis vaccine | Montana University | National Institutes of Health | $12.30 | 10/29/2023 |
| NHLBI to award Mount Sinai Health System grant to compare new treatment options against sickle cell disease | Mount Sinai Health System Inc. | National Heart Lung and Blood Institute | $12.10 | 10/12/2023 |
| American Lung Association to award Mount Sinai funding to conduct research in NK cell therapy against lung cancer | Mount Sinai School of Medicine | American Lung Association | Payment unspecified | 10/12/2023 |
| CSL to award Nanyang Technological University funding to conduct research on methods using DNA repair proteins for insertional gene editing in human cells | Nanyang Technological University | CSL Ltd. | $0.33 | 10/4/2023 |
| NIA to award Neurodon grant to develop SERCA enzyme activators for Alzheimer's disease | Neurodon Corp. | National Institute on Aging | $2.90 | 10/3/2023 |
| IIA to grant Nurexone funding to develop Exopten against complex chronic spinal cord injury | Nurexone Biologic Inc. | Israel Innovation Authority | $0.26 | 10/11/2023 |
| Falk Medical Research Trust to award Ocean Biomedical funding to advance a new class of antimalarial drug candidates | Ocean Biomedical Inc. | Falk Medical Research Trust | $1.00 | 10/24/2023 |
| Spanish State Research Agency to award Oryzon funding to study the role of epigenetic targets in the treatment of neuronal pathologies | Oryzon Genomics SA | Spanish State Research Agency | Payment unspecified | 10/3/2023 |
| Delaware Community Foundation to award Penn Medicine funding to develop therapies against ADRD | Penn Medicine | Delaware Community Foundation | $5.00 | 10/30/2023 |
| CSL to award Philipps-Universitat Marburg funding to identify the long non-coding RNAs for precision biotherapies against SIRS | Philipps-Universitat Marburg | CSL Ltd. | $0.33 | 10/4/2023 |
| NINDS to award Prilenia Therapeutics funding to conduct EAP for pridopidine against amyotrophic lateral sclerosis | Prilenia Therapeutics B.V | National Institute of Neurological Disorders and Stroke | Payment unspecified | 10/5/2023 |
| NIH to award Rational Vaccines grant to advance research against Herpes Simplex Virus | Rational Vaccines Inc. | National Institutes of Health | $2.80 | 10/13/2023 |
| DRDC to award Revive funding to evaluate Bucillamine for nerve agent exposure | Revive Therapeutics Ltd | Canadian Department of National Defence | Payment unspecified | 10/17/2023 |
| Mark Foundation to award Stanford School of Medicine funding to engineer multi-modal immunotherapies against small-cell neuroendocrine tumors | Stanford University School of Medicine | The Mark Foundation for Cancer Research | $3.00 | 10/17/2023 |
| Bill & Melinda Gates Foundation to award Strm.bio funding to develop in vivo gene therapy delivery platform | Strm.bio | Bill & Melinda Gates Foundation | Payment unspecified | 10/4/2023 |
| The Mark Foundation for Cancer Research to award Takeda funding for research on cancer therapeutics | Takeda Pharmaceutical Co Ltd | The Mark Foundation for Cancer Research | Payment unspecified | 10/12/2023 |
| American Lung Association to award Texas Biomedical Research Institute funding to develop a universal flu vaccine | Texas Biomedical Research Institute | American Lung Association | $0.50 | 10/4/2023 |
| NINDS to award Massachusetts General Hospital funding to support the clinical study of RAPA-501 for ALS | The General Hospital Corp. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 10/5/2023 |
| NCI to award Traverse Biotech Phase I SBIR grant to develop bispecific antibody against non-small-cell lung cancer | Traverse Biotech Inc. | National Cancer Institute | Payment unspecified | 10/18/2023 |
| NINDS to award UCLA School of Dentistry grant to develop a non addictive cannabis based pain medication for oral cancer pain | UCLA School of Dentistry | National Institute of Neurological Disorders and Stroke | $5.00 | 10/20/2023 |
| CSL to award Universite Paris SACLAY funding to develop therapeutic nanobodies for vaso occlusive crisis in sickle cell disease | Université Paris-Saclay | CSL Ltd. | $0.33 | 10/4/2023 |
| Cancer Research UK to award UCL funding to conduct research role of NK cells and develop therapeutics against multiple myeloma | University College London | Cancer Research UK | Payment unspecified | 10/30/2023 |
| PolG Foundation to award University of Bergen's grant to discover mitochondria-targeting therapies for POLG disease | University of Bergen | PolG Foundation | Payment unspecified | 10/10/2023 |
| Spencer Dayman Meningitis Research to award University of Bristol funding to develop a vaccine against invasive group A streptococcus | University of Bristol | Spencer Dayman Meningitis Research | Payment unspecified | 10/9/2023 |
| NIA to award University of California San Francisco grant to conduct Alzheimer’s Tau Platform (ATP) trial against Alzheimer’s disease | University of California San Francisco | National Institute on Aging | $151.00 | 10/12/2023 |
| CSL to award University of Cambridge funding to conduct research on mRNA-based solutions, to minimize the loss of HSC function in ex vivo gene therapy protocol | University of Cambridge | CSL Ltd. | $0.33 | 10/4/2023 |
| UKRI to award University of Cambridge funding to enhance the SARS-CoV-2 vaccine strain against COVID-19 infection | University of Cambridge | United Kingdom Research & Innovation | $27.21 | 10/10/2023 |
| Bayer to award University of Chicago funding to conduct research on darolutamide against prostate cancer | University of Chicago | Prostate Cancer Foundation | $1.00 | 10/25/2023 |
| JDRF to award University of Dundee grant to support clinical trial to advance treatment for people with type 1 diabetes and heart failure | University of Dundee | Juvenile Diabetes Research Foundation Ltd. | Payment unspecified | 10/25/2023 |
| Parkinson’s UK to award funding for two projects at the University of Edinburgh to build a model of PD in a dish and to study on the role of the LRRC37A2 gene in PD | University of Edinburgh | Parkinson's UK Sales Ltd. | $0.51 | 10/17/2023 |
| PolG Foundation to award University of Helsinki funding to identify the target and to develop therapies for POLG disease | University of Helsinki | PolG Foundation | Payment unspecified | 10/10/2023 |
| CARB-X to award University of Melbourne funding to develop PBT-2 against community-acquired bacterial pneumonia | University of Melbourne | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $1.75 | 10/3/2023 |
| NINDS to award University of Miami HEAL UG3 grant to advance Adolore's ADB-102 against chronic osteoarthritis knee pain | University of Miami | National Institute of Neurological Disorders and Stroke | Payment unspecified | 10/3/2023 |
| CSL to award University of Toulouse funding Toulouse to conduct research on regulatory T cells for autoimmune myositis and muscle injury | University of Toulouse | CSL Ltd. | $0.33 | 10/4/2023 |
| U.S. Department of Defense to award Vaccine and Immunotherapy Center funding to advance development of a self-assembling vaccine platform for rapid production of prophylactic vaccines for various infectious diseases | Vaccine and Immunotherapy Center | U.S. Department of Defense | $5.88 | 10/5/2023 |
| BARDA to award Venatorx Pharmaceuticals funding to develop oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis | Venatorx Pharmaceuticals Inc. | Biomedical Advanced Research and Development Authority | $167.00 | 10/11/2023 |
| BARDA to award Vir Biotechnology funding to support development of a monoclonal antibody targeting coronaviruses that cause COVID-19 and other pandemic infections | Vir Biotechnology Inc. | Biomedical Advanced Research and Development Authority | $50.00 | 10/4/2023 |
| NCI to award Washington University School of Medicine in St Louis to develop new therapies for pancreatic ductal adenocarcinoma | Washington University School of Medicine in St Louis | National Cancer Institute | $10.90 | 10/17/2023 |
| DoD to award Weill Cornell Medicine to conduct research on metastasis in bladder cancer | Weill Cornell Medicine | U.S. Department of Defense | $0.61 | 10/2/2023 |
| Vinnova to award XNK Therapeutics funding to support the preclinical project for cancer | XNK Therapeutics AB | Vinnova | $0.16 | 10/10/2023 |
| NIH to award funding to Yale School of Medicine to develop CRISPR-based gene therapy platform for genetic brain diseases, Angelman syndrome and HIST1H1E syndrome | Yale School of Medicine | National Institutes of Health | $40.00 | 10/3/2023 |
| JDRF to award Yale funding to explore the use of the AIM nanoparticles in combination with an anti-CD3 monoclonal antibody to tolerize, deplete or modulate diabetes antigen-specific T cells | Yale School of Medicine | Juvenile Diabetes Research Foundation | $0.30 | 10/24/2023 |
| French National Research Agency to award AB Science grant to conduct phase II trial of masitinib against sickle cell disease | AB Science SA | French National Research Agency | $10.01 | 11/27/2023 |
| Erling-Persson Foundation to award Akiram Therapeutics funding to develop antibody-drug conjugate radiopharmaceuticals to treat aggressive cancers | Akiram Therapeutics AB | Erling-Persson Foundation | $5.70 | 11/27/2023 |
| LLS to award Albert Einstein College of Medicine funding to develop therapies against myeloid cancer | Albert Einstein College of Medicine | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| National Institutes of Aging to award Amydis funding to develop small-molecule retinal tracer targeting the biomarker tau for detecting and diagnosing Alzheimer’s disease and other tauopathies | Amydis Inc. | National Institutes of Aging | Payment unspecified | 11/14/2023 |
| Walloon region to award Amyl Therapeutics funding to develop Amyl technology platform to treat neurodegenerative diseases and AL amyloidosis | Amyl Therapeutics Srl | Walloon region | $6.40 | 11/7/2023 |
| LifeArc to award Cardiff University funding to develop an antibody therapy targeting complement of the innate immune system for treatment of Alzheimer’s disease | Cardiff University | LifeArc | Payment unspecified | 11/13/2023 |
| ACRF to award Children’s Cancer Institute funding for the immunotherapy research against childhood cancer | Children's Cancer Institute | Australian Cancer Research Foundation | Payment unspecified | 11/16/2023 |
| LLS to award Children's Hospital of Philadelphia funding to conduct research on CAR T-immunotherapy against acute lymphoblastic leukemia | Childrens Hospital of Philadelphia | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| Paul G. Allen Foundation to award Columbia University funding to study on optical tools for visualizing sex hormones as drivers of dynamic internal states | Columbia University | The Paul G. Allen Family Foundation | Payment unspecified | 11/21/2023 |
| LLS to award Dren Bio to conduct a phase I clinical study on antibody against large granular lymphocytic leukemia | Dren Bio Inc. | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| U.S. Biomedical Advanced Research and Development Authority awarded a $75M option to Emergent’s existing contract for the acquisition of Cyfendus for anthrax | Emergent Biosolutions Inc. | U.S. Biomedical Advanced Research and Development Authority | $75.00 | 11/28/2023 |
| U.K. Department of Health and Social Care’s U.K. Vaccine Network to award Emergex Vaccines funding to develop CD8 T-cell-based vaccine candidate against Chikungunya virus | Emergex Vaccines Holding Ltd. | U.K. Department of Health and Social Care’s U.K. Vaccine Network | $2.23 | 11/17/2023 |
| NHMRC to award Garvan Institute synergy grants to develop CAR T cell therapy for solid tumours and to prevent lethal metastases. | Garvan Institute of Medical Research | National Health and Medical Research Council | Payment unspecified | 11/23/2023 |
| CPRIT to award Gradalis funding to advance the phase II clinical study of Vigil for ovarian cancer | Gradalis Inc | Cancer Prevention and Research Institute of Texas | $9.90 | 11/16/2023 |
| NIH to award Hillhurst Biopharmaceuticals funding to develop HBI-201 for pain | Hillhurst Biopharmaceuticals Inc. | National Institutes of Health | $2.00 | 11/7/2023 |
| LLS to award Immune-Onc to conduct a dose expansion clinical trial study on an antibody targeting LILRB4 in combination with chemotherapy against CMML and AML | Immune-Onc Therapeutics Inc. | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| LifeArc to award Imperial College London funding to repurpose an anti-anxiety drug to treat small vessel disease | Imperial College London | LifeArc | Payment unspecified | 11/13/2023 |
| LLS to award Indiana University to evaluate the safety and effectiveness of a CAR T-immunotherapy against chronic myelomonocytic leukemia | Indiana University | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| U.S Army Medical Research and Development Command to award Inhalon Biopharma funding to develop new treatments for COVID-19 and other SARS infections | Inhalon Biopharma Inc. | U.S Army Medical Research and Development Command | $5.70 | 11/15/2023 |
| American Crohn’s & Colitis Foundation to award Inotrem funding to develop INO-02 for inflammatory bowel disease and development of a biomarker-based personalized approach | Inotrem SA | American Crohn’s & Colitis Foundation | Payment unspecified | 11/6/2023 |
| NHMRC to award James Cook University funding to support the development of drugs against aneurysm | James Cook University | National Health and Medical Research Council | $5.00 | 11/24/2023 |
| Johns Hopkins University School of Medicine to receive funding from The Paul G. Allen Family Foundation to investigate EV corona | Johns Hopkins University School of Medicine | The Paul G. Allen Family Foundation | Payment unspecified | 11/21/2023 |
| Erling-Persson Foundation to award KI researchers funding to support phase I clinical trial of stem cell therapy against macular degeneration | Karolinska Institutet | Familjen Erling-Perssons Stiftelse | $0.92 | 11/7/2023 |
| LifeArc to award King's College London funding to research on a gene therapy approach for amyotrophic lateral sclerosis and fronto-temporal dementia | King's College London | LifeArc | Payment unspecified | 11/13/2023 |
| Charite to award Kyverna funding to investigate B and plasma cell targeting therapies against systemic autoimmune diseases | Kyverna Therapeutics Inc. | Charite University Hospital Berlin | Payment unspecified | 11/1/2023 |
| Bpifrance to award Maat Pharma funding to support the phase IIb Phoebus trial of MaaT-033 against cancer | Maat Pharma SA | Bpifrance | $8.05 | 11/30/2023 |
| Cancer Focus Fund to invest in March Biosciences to conduct a phase II clinical trial of MB-105 against T-cell leukemias and lymphomas | March Biosciences Inc. | Cancer Focus Fund | $4.80 | 11/9/2023 |
| CPRIT to award March Biosciences grant to support phase II clinical trial of MB-105 for the treatment of relapsed and refractory T-cell lymphomas | March Biosciences Inc. | Cancer Prevention and Research Institute of Texas | $13.40 | 11/17/2023 |
| LLS to award MD Anderson Cancer Center funding to evaluate antibodies and immunotherapy against cancer | MD Anderson Cancer Center | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| National Health and Medical Research Council to award Monash University grant to investigate CAR T cell therapy for prostate cancer | Monash University | National Health and Medical Research Council | $5.00 | 11/20/2023 |
| European Union to award Nemysis funding to develop E-40 against celiac disease | Nemysis Ltd. | The European Union | $2.72 | 11/7/2023 |
| Michael J. Fox Foundation for Parkinson’s Research to award Octave Bioscience funding for discovery, development and validation of a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic | Octave Bioscience Inc. | Michael J. Fox Foundation for Parkinson’s Research | $10.00 | 11/16/2023 |
| Bpifrance to award Oncovita funding to develop MVP-06-01 against solid tumor | Oncovita SAS | Bpifrance | $4.90 | 11/29/2023 |
| NIH to award Orlance Phase II SBIR grant to advance MACH-1 delivery platform and influenza vaccine for flu and future pandemics toward phase I clinical trials | Orlance Inc. | National Institutes of Health | $3.00 | 11/28/2023 |
| Department of Defense to award Penn Medicine funding to support the research on biomarkers against TBI | Penn Medicine | US Department of Defense | $8.00 | 11/16/2023 |
| LLS to award Peter MacCallum Cancer Centre funding to advance immunotherapy against B-cell leukemia | Peter MacCallum Cancer Centre | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 11/1/2023 |
| Canadian Institutes of Health Research to award Qu Biologics grant to support PERIOP-06 phase II trial of QBECO for metastatic colorectal adenocarcinoma | Qu Biologics Inc | Canadian Institutes of Health Research | 0.3 | 11/14/2023 |
| California Institute for Regenerative Medicine to award Ray Therapeutics funding to develop RTx-021 for geographic atrophy | Ray Therapeutics Inc. | California Institute for Regenerative Medicine | $4.00 | 11/13/2023 |
| European Innovation Council to award Resother Pharma funding to support phase IIa study of RTP-026 against myocardial infarction | Resother Pharma ApS | European Commission | $2.72 | 11/6/2023 |
| Department of Defense award funding to evaluate Rion’s purified exosome product as a treatment for chronic obstructive pulmonary disease and other pulmonary conditions | Rion Inc. | Department of Defense | $2.40 | 11/20/2023 |
| California Institute for Regenerative Medicine to award Siren Biotechnology funding to develop AAV immuno-gene therapies for the treatment of cancer | Siren Biotechnology Inc. | California Institute for Regenerative Medicine | $4.00 | 11/3/2023 |
| LLS to award St Jude Children's Research Hospital funding to evaluate CAR T-immunotherapy targeting CD70 in acute myelogenous leukemia children | St Jude Children's Research Hospital | The Leukemia & Lymphoma Society Inc | Payment unspecified | 11/1/2023 |
| Paul G. Allen Family Foundation to award University of California San Diego funding to support study on extracellular vesicles in brain health | University of California San Diego | The Paul G. Allen Family Foundation | $1.50 | 11/21/2023 |
| NCI to award Weill Cornell Medicine a MERIT grant to support research on APOBEC3 proteins related to bladder cancer | Weill Cornell Medicine | National Cancer Institute | $4.00 | 11/21/2023 |
| Flanders Innovation & Entrepreneurship to award Astrivax funding to develop therapeutic vaccine for chronic hepatitis B | Astrivax BV | Flanders Innovation & Entrepreneurship | $3.20 | 12/13/2023 |
| CEPI and Barinthus to expedite the development of VTP-500 for the prevention of MERS coronavirus | Barinthus Biotherapeutics plc | Coalition for Epidemic Preparedness Innovations | $34.80 | 12/21/2023 |
| NCCN to award Beth Israel funding to evaluate a personalized cancer vaccine in conjunction with elranatamab for multiple myeloma | Beth Israel Deaconess Medical Center | National Comprehensive Cancer Network Inc | $5.00 | 12/19/2023 |
| National Institute of Allergy and Infectious Diseases to award Cadence Molecular Sciences funding to provide its molecular design software to power the open-science artificial intelligence-driven structure-enabled antiviral platform discovery consortium to develop antivirals | Cadence Molecular Sciences | National Institute of Allergy and Infectious Diseases | $68.00 | 12/7/2023 |
| NIAAA to award Camino Pharma funding to develop PAMs mGlu2 for the treatment of alcohol use disorder | Camino Pharma LLC | National Institute on Alcohol Abuse and Alcoholism | $1.97 | 12/7/2023 |
| Department of Defense to award Cedars-Sinai Medical Center grant to advance personalized cancer treatments | Cedars-Sinai Medical Center | US Department of Defense | $3.20 | 12/18/2023 |
| NEA to award Children's Hospital of Philadelphia grant to study on genetic landscape of pediatric patients with monogenic susceptibilities to atopic dermatitis | Childrens Hospital of Philadelphia | National Eczema Association | Payment unspecified | 12/12/2023 |
| NICHD to award Dare Bioscience grant to support development of DARE-PTB1 as treatment to prevent preterm birth | Daré Bioscience Inc. | Eunice Kennedy Shriver National Institute of Child Health & Human Development | $2.00 | 12/13/2023 |
| National Institute on Drug Abuse to award Delix Therapeutics funding to develop DLX-007 for substance-use disorders | Delix Therapeutics Inc. | National Institute on Drug Abuse | $0.32 | 12/13/2023 |
| Karolinska Institutet to award Dutch Brain Foundation to study on NOTCH3 immunotherapy to target toxic protein aggregation in CADASIL | Dutch Brain Foundation | Karolinska Institutet | $0.27 | 12/15/2023 |
| Bill & Melinda Gates Foundation to award Evotec grant for teratogenicity platform technology | Evotec SE | Bill & Melinda Gates Foundation Trust | $2.50 | 12/19/2023 |
| Open Philanthropy to award Exscientia funding to support the development of a therapeutic for pandemic influenza by harnessing the host interferon response | Exscientia plc | Open Philanthropy | $2.30 | 12/5/2023 |
| Global Health Innovative Technology Fund to award Fosun Pharmaceutical funding to support the phase III study of the combination of artemether, lumefantrine and amodiaquine against malaria in Africa and Southeast Asia | Fosun Pharmaceutical Group Co. Ltd. | Global Health Innovative Technology Fund | $3.30 | 12/14/2023 |
| NEA to award Harvard College funding to study on Staphylococcus aureus neuroimmune signaling in itch and skin barrier damage in eczema | Harvard University | National Eczema Association | Payment unspecified | 12/12/2023 |
| Research Council of Norway to award Hemispherian grant to develop drug candidates to treat platinum resistant ovarian cancers | Hemispherian AS | The Research Council of Norway | $1.53 | 12/19/2023 |
| NCCN to award Indiana University funding to study on response-guided treatment discontinuation of elranatamab in elderly patients with MM | Indiana University Melvin and Bren Simon Cancer Center | National Comprehensive Cancer Network Inc. | $5.00 | 12/19/2023 |
| Bill & Melinda Gates Foundation to award IAVI funding to support phase IIb trial of MTBVAC against tuberculosis | International AIDS Vaccine Initiative | Bill & Melinda Gates Foundation Trust | $55.00 | 12/18/2023 |
| MJFF to award Irlab funding to conduct phase I study of IRL-757 against apathy | Irlab Therapeutics AB | The Michael J Fox Foundation for Parkinson's Research | $2.00 | 12/21/2023 |
| Swedish Research Council to award KI funding to support clinical therapy studies | Karolinska Institutet | Swedish Research Council | $7.48 | 12/4/2023 |
| SHLF to award KI funding to develop bacteriophage therapy for the treatment of pseudomonas infections in patients with cystic fibrosis | Karolinska Institutet | Swedish Heart Lung Foundation | $0.28 | 12/8/2023 |
| LLS to award Kura Oncology funding to support phase I study of Ziftomenib against pediatric acute leukemia | Kura Oncology Inc | The Leukemia & Lymphoma Society Inc. | Payment unspecified | 12/8/2023 |
| BMGF to award LTS funding to develop thermostable mRNA/LNP MAP against infectious diseases in low- and middle-income countries | LTS Lohmann Therapie-Systeme AG | Bill & Melinda Gates Foundation Trust | $1.20 | 12/6/2023 |
| Horizon Europe to award MARVAX consortium' funding to conduct research and develop vaccines against Marburg viruses | Malaria Research Capacity Development in West and Central Africa Consortium | The European Union | $8.05 | 12/14/2023 |
| GI Research Foundation to award MD Anderson Cancer Center funding to support the study on BRAF-mutated colorectal cancer treatments | MD Anderson Cancer Center | Gastro-Intestinal Research Foundation Inc. | $3.50 | 12/13/2023 |
| U.S. Department of Defense, through the Medical Technology Enterprise Consortium to award Mediwound additional funding to develop Nexobrid as a nonsurgical solution for field-care burn treatment for the U.S. Army | Mediwound Ltd. | U.S. Department of Defense | $6.70 | 12/28/2023 |
| Cancer Council to award BDI funding for the research on CAR-T therapies against mesothelioma and prostate cancer | Monash Biomedicine Discovery Institute | The Cancer Council Victoria | $0.90 | 12/13/2023 |
| Antisense Therapeutics to award MCRI funding to conduct research on ATL-1102 against Duchenne muscular dystrophy | Murdoch Children’s Research Institute | Antisense Therapeutics Ltd. | Payment unspecified | 12/13/2023 |
| University of Melbourne to award MCRI funding to develop precision therapies and stem cell-based therapies for mitochondrial disease and kidney disease | Murdoch Childrens Research Institute | University of Melbourne | Payment unspecified | 12/20/2023 |
| Bill & Melinda Gates Foundation to award Naobios funding to support vaccine development for infections | Naobios | Bill & Melinda Gates Foundation | $1.87 | 12/11/2023 |
| Dutch Cancer Society to award Netherlands Cancer Institute funding to conduct a study on combination treatment with HIPEC and PARP-inhibitors and to develop a smart device against ovarian and rectal cancer | Netherlands Cancer Institute | Dutch Cancer Society | Payment unspecified | 12/12/2023 |
| ALS Association to award Oryzon funding to support preclinical study of ORY-4001 against amyotrophic lateral sclerosis | Oryzon Genomics SA | The Amyotrophic Lateral Sclerosis Association | $0.50 | 12/4/2023 |
| NIAID to award Osivax grant to support preclinical evaluation of OVX-836 to provide protection against pandemic influenza strains | Osivax SAS | National Institute of Allergy and Infectious Diseases | $1.50 | 12/5/2023 |
| Spanish Ministry of Science and Innovation to award Peptomyc soft loan to advance the clinical development of OMO-103 against brain metastasis | Peptomyc SL | Spanish Ministry of Science and Innovation | $2.83 | 12/20/2023 |
| KDDF to fund Pharmabcine’s phase I clinical study of PMC-403 for patients with neovascular age-related macular degeneration in Korea | Pharmabcine Inc. | Korea Drug Development Fund | Payment unspecified | 12/4/2023 |
| NIDA to award Pharmnovo funding to evaluate PN-6047 in a preclinical model, for opioid withdrawal syndrome | Pharmnovo AB | National Institute on Drug Abuse | Payment unspecified | 12/4/2023 |
| Bill & Melinda Gates Foundation to award Radiant Biotherapeutics grant to develop therapeutics using Multabody platform against HIV | Radiant Biotherapeutics Inc. | Bill & Melinda Gates Foundation Trust | $2.00 | 12/20/2023 |
| US Government to award a non-dilutive external Redhill funding to conduct a ACESO PROTECT adaptive platform trial on RHB-107 against COVID-19 | Redhill Biopharma Ltd. | US Government | $4.80 | 12/4/2023 |
| NCCN to award Siteman Cancer Center funding to support clinical studies of elranatamab against multiple myeloma | Siteman Cancer Center | National Comprehensive Cancer Network Inc. | $5.00 | 12/19/2023 |
| Swiss Innovation Agency to award grant to Topadur to conduct research on treatments including TOP-N53 for vasospasm, digital ulcers and Raynaud's disease | Topadur Pharma AG | Innosuisse Management AG | Payment unspecified | 12/20/2023 |
| KIAT to award funding to Topadur Pharma to conduct research on project focusing on treatments including TOP-N53 for vasospasm, digital ulcers and Raynaud's disease | Topadur Pharma AG | Korea Institute for Advancement of Technology | Payment unspecified | 12/20/2023 |
| NCCN to award UC San Diego funding to conduct a phase II MRD adapted study of elranatamab in r/r multiple myeloma | UC San Diego Moores Cancer Center | National Comprehensive Cancer Network Inc | $5.00 | 12/19/2023 |
| Novo Nordisk Foundation to award University of Copenhagen funding to develop vaccines against tuberculosis and influenza | University of Copenhagen | Novo Nordisk Foundation | $262.81 | 12/18/2023 |
| Bill & Melinda to award Vitrivax funding to develop ALTA, a thermostabilization vaccine technology and to develop a pilot-scale manufacturing capacity | Vitrivax Inc. | Bill & Melinda Gates Foundation Trust | $5.00 | 12/6/2023 |
| NIAID to award Vyramed funding to conduct research on MTP technology against varicella zoster virus | Vyramed LLC | National Institute of Allergy and Infectious Diseases | Payment unspecified | 12/7/2023 |
| Bill & Melinda Gates Foundation to award Weill Cornell Medicine grants for tuberculosis drug development | Weill Cornell Medicine | Bill & Melinda Gates Foundation Trust | $6.80 | 12/21/2023 |
| NEA to award Yale University to conduct research on Vista against eczema | Yale University | National Eczema Association | Payment unspecified | 12/12/2023 |